[go: up one dir, main page]

EP3136986B1 - Dispositif d'occlusion - Google Patents

Dispositif d'occlusion Download PDF

Info

Publication number
EP3136986B1
EP3136986B1 EP15720947.9A EP15720947A EP3136986B1 EP 3136986 B1 EP3136986 B1 EP 3136986B1 EP 15720947 A EP15720947 A EP 15720947A EP 3136986 B1 EP3136986 B1 EP 3136986B1
Authority
EP
European Patent Office
Prior art keywords
aneurysm
occlusion device
marker
mesh
occlusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP15720947.9A
Other languages
German (de)
English (en)
Other versions
EP3136986A1 (fr
Inventor
Stephen Griffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerus Endovascular Ltd
Original Assignee
Cerus Endovascular Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerus Endovascular Ltd filed Critical Cerus Endovascular Ltd
Priority to EP21206876.1A priority Critical patent/EP3970635A1/fr
Priority to EP19159876.2A priority patent/EP3510945B1/fr
Publication of EP3136986A1 publication Critical patent/EP3136986A1/fr
Application granted granted Critical
Publication of EP3136986B1 publication Critical patent/EP3136986B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12168—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
    • A61B17/12172—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure having a pre-set deployed three-dimensional shape
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027—Type of occlusion
    • A61B17/12031—Type of occlusion complete occlusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • A61B17/12113—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel within an aneurysm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12168—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B2017/00831—Material properties
    • A61B2017/00867—Material properties shape memory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205—Introduction devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205—Introduction devices
    • A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
    • A61B2017/12063—Details concerning the detachment of the occluding device from the introduction device electrolytically detachable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3937—Visible markers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3966—Radiopaque markers visible in an X-ray image

Definitions

  • the present invention relates generally to the field of occlusion devices.
  • an aneurysm forms when a dilated portion of an artery is stretched thin from the pressure of the blood.
  • the weakened part of the artery forms a bulge, or a ballooning area, that risks leak and/or rupture.
  • a neurovascular aneurysm ruptures, it causes bleeding into the compartment surrounding the brain, the subarachnoid space, causing a subarachnoid hemorrhage.
  • Subarachnoid hemorrhage from a ruptured neurovascular aneurysm can lead to a hemorrhagic stroke, brain damage, and death.
  • Approximately 25 percent of all patients with a neurovascular aneurysm suffer a subarachnoid hemorrhage.
  • Neurovascular aneurysms occur in two to five percent of the population and more commonly in women than men. It is estimated that as many as 18 million people currently living in the United States will develop a neurovascular aneurysm during their lifetime. Annually, the incidence of subarachnoid hemorrhage in the United States exceeds 30,000 people. Ten to fifteen percent of these patients die before reaching the hospital and over 50 percent die within the first thirty days after rupture. Of those who survive, about half suffer some permanent neurological deficit.
  • EDS Ehlers-Danlos syndrome
  • unruptured aneurysms are asymptomatic. Some people with unruptured aneurysms experience some or all of the following symptoms: peripheral vision deficits, thinking or processing problems, speech complications, perceptual problems, sudden changes in behavior, loss of balance and coordination, decreased concentration, short term memory difficulty, and fatigue. Symptoms of a ruptured neurovascular aneurysm include nausea and vomiting, stiff neck or neck pain, blurred or double vision, pain above and behind the eye, dilated pupils, sensitivity to light, and loss of sensation. Sometimes patients describing "the worst headache of my life" are experiencing one of the symptoms of a ruptured neurovascular aneurysm.
  • CSF cerebrospinal fluid
  • Cerebral angiography the traditional method, involves introducing a catheter into an artery (usually in the leg) and steering it through the blood vessels of the body to the artery involved by the aneurysm.
  • a special dye called a contrast agent, is injected into the patient's artery and its distribution is shown on X-ray projections. This method may not detect some aneurysms due to overlapping structures or spasm.
  • Computed Tomographic Angiography is an alternative to the traditional method and can be performed without the need for arterial catheterization.
  • This test combines a regular CT scan with a contrast dye injected into a vein. Once the dye is injected into a vein, it travels to the brain arteries, and images are created using a CT scan. These images show exactly how blood flows into the brain arteries.
  • New diagnostic modalities promise to supplement both classical and conventional diagnostic studies with less-invasive imaging and possibly provide more accurate 3-dimensional anatomic information relative to aneurismal pathology. Better imaging, combined with the development of improved minimally invasive treatments, will enable physicians to increasingly detect, and treat, more silent aneurysms before problems arise.
  • open craniotomy is a procedure by which an aneurysm is located, and treated, extravascularly.
  • This type of procedure has significant disadvantages.
  • the patient undergoes a great deal of trauma in the area of the aneurysm by virtue of the fact that the surgeon must sever various tissues in order to reach the aneurysm.
  • the surgeon In treating cerebral aneurysms extravascularly, for instance, the surgeon must typically remove a portion of the patient's skull, and must also traumatize brain tissue in order to reach the aneurysm. As such, there is a potential for the development of epilepsy in the patients due to the surgery.
  • embolic material includes, for example, detachable coils or an embolic agent, such as a liquid polymer.
  • the injection of these types of embolic materials suffers from disadvantages, most of which are associated with migration of the embolic material out of the aneurysm into the parent artery. This can cause permanent and irreversible occlusion of the parent artery.
  • the detachable coils when detachable coils are used to occlude an aneurysm which does not have a well-defined neck region, the detachable coils can migrate out of the sac of the aneurysm and into the parent artery. Further, it is at times difficult to gauge exactly how full the sac of the aneurysm is when detachable coils are deployed. Therefore, there is a risk of overfilling the aneurysm in which case the detachable coils also spill out into the parent artery.
  • detachable coils involves coil compaction over time. After filling the aneurysm, there remains space between the coils. Continued hemodynamic forces from the circulation act to compact the coil mass resulting in a cavity in the aneurysm neck. Thus, the aneurysm can recanalize.
  • Embolic agent migration is also a problem. For instance, where a liquid polymer is injected into the sac of the aneurysm, it can migrate out of the sac of the aneurysm due to the hemodynamics of the system. This can also lead to irreversible occlusion of the parent vessel.
  • Such techniques are, without limitation, temporary flow arrest and parent vessel occlusion, and typically involve temporarily occluding the parent vessel proximal of the aneurysm, so that no blood flow occurs through the parent vessel, until a thrombotic mass has formed in the sac of the aneurysm.
  • this helps reduce the tendency of the embolic material to migrate out of the aneurysm sac.
  • a thrombotic mass can dissolve through normal lysis of blood.
  • even occluding the parent vessel may not prevent all embolic material migration into the parent vessel.
  • Another endovascular technique for treating aneurysms involves inserting a detachable balloon into the sac of the aneurysm using a microcatheter.
  • the detachable balloon is then inflated using saline and/or contrast fluid.
  • the balloon is then detached from the microcatheter and left within the sac of the aneurysm in an attempt to fill the sac of the aneurysm.
  • detachable balloons also suffer disadvantages and as such this practice has all but been superseded by the current practice of deployment of coils or other types of occlusion devices.
  • detachable balloons when inflated, typically will not conform to the interior configuration of the aneurysm sac.
  • the detachable balloon requires the aneurysm sac to conform to the exterior surface of the detachable balloon. Thus, there is an increased risk that the detachable balloon will rupture the sac of the aneurysm. Further, detachable balloons can rupture and migrate out of the aneurysm.
  • Another endovascular technique for treating aneurysms involves occlusion devices having two expandable lobes and a waist, or an expandable body portion, a neck portion, and a base portion.
  • Still another endovascular technique for treating aneurysms involves occlusion devices for intrasaccular implantation having a body portion designed to fill and/or expand radially into the space within the sac of the aneurysm.
  • the present invention provides innovative improvements and several advantages in the field of vascular occlusion devices because the occlusion device disclosed herein provides aneurysm treatment and/or amelioration, particularly for neurovascular aneurysms, via the use of a minimum amount of fully-retrievable deployable material.
  • the configuration of such an oversized occlusion device eliminates the need for additional material for pinning the aneurysm neck and/or for an anchoring mechanism in the parent vessel adjacent to the aneurysm and/or for spherical, radial expansion of the body portion of the device into the sac of the aneurysm.
  • Document US2004/044391 discloses an occluder according to the preamble of claim 1.
  • the present invention is disclosed in the appended set of claims.
  • the present inventor has designed an occlusion device for providing aneurysm treatment and/or amelioration through the use of a minimum amount of fully-retrievable deployable low profile resilient mesh material which is oversized to the diameter of the aneurysm.
  • an occlusion device having less material than the current standard device, minimizes the need for anti-coagulation therapy and/or lessens the risk of clot emboli formation which could flow deeper into the vascular tree inducing stroke.
  • Such an implantable occlusion device is also used for treatment of vessel occlusion and/or peripheral vascular embolization.
  • an occlusion device for implantation within the sac of an aneurysm comprising: (a) a solid marker having a proximal end and a distal end; and (b) a resilient mesh body attached to the distal end of the marker, the body having a delivery shape and a low profile shape having a height that is between 10% to 20% of its width in free air capable of conforming to aneurysm walls; the occlusion device being characterized in that the resilient mesh body is a dual layer of mesh which comprises a single layer of mesh folded circumferentially to create a circumferential fold line around the circumference of the body, and folded over ends of resilient mesh, wherein all the folded over ends of the dual layer of the mesh are within the marker.
  • the deployed shape of the resilient mesh body of the occlusion device is capable of apposing an aneurysm dome.
  • the proximal end of the marker of the occlusion device is capable of sealing an aneurysm neck.
  • the marker is a radiopaque marker
  • the marker is a detachment junction to deploy the occlusion device
  • the marker is an attachment junction to retrieve the occlusion device
  • the marker comprises a rigid member
  • the marker is a solid ring.
  • kits comprising the occlusion device disclosed herein and a delivery means for deploying the occlusion device.
  • an occlusion device delivery system corresponds to (or is compatible with) an occlusion device for deployment thereof.
  • occlusion device means and/or may be interchangeable with terminology such as, without limitation, “device” or “occlusion device system” or “occlusion system” or “system” or “occlusion device implant” or “implant” or “intrasaccular implant” and the like.
  • Occlusion device delivery systems are well known and readily available in the art. For example, such delivery technologies may be found, without limitation, in US Patent and Publication Numbers 4,991,602 ; 5,067,489 ; 6,833,003 ; 2006/0167494 ; and 2007/0288083 .
  • any type of occlusion device delivery means and/or delivery system and/or delivery technology and/or delivery mechanism and/or detachment (and/or attachment) means and/or detachment system and/or detachment technology and/or detachment mechanism may be utilized and/or modified in such a manner as to make compatible (so as to correspond) with the occlusion device disclosed herein.
  • Exemplary occlusion device delivery mechanisms and/or systems include, without limitation, guide wires, pusher wires, catheters, micro-catheters, and the like.
  • Exemplary occlusion device detachment mechanisms include, without limitation, fluid pressure, electrolytic mechanisms, hydraulic mechanisms, interlocking mechanisms, and the like.
  • the occlusion device disclosed herein is used in a method of electrolytic detachment. Electrolytic detachment is well known in the art and can be found, for example, in US Patent Numbers 5,122,136 ; 5,423,829 ; 5,624,449 ; 5,891,128 ; 6,123,714 ; 6,589,230 ; and 6,620,152 .
  • Figure 1A and Figure 3A show an embodiment of an occlusion device as disclosed herein for intrasaccular implantation within an 10 aneurysm to be treated.
  • Figure 1A and Figure 3A also shows the diameter (x) of the 14 resilient mesh body of such an occlusion device in "free air". As is accepted in the art, the diameter of such an occlusion device is measured in free air.
  • the 14 resilient mesh body of the occlusion device is "oversized" relative to the 10 aneurysm and therefore has a diameter (x) greater than the diameter (y) of the 10 aneurysm ( i.e ., ⁇ x > ⁇ y) to be treated as shown in Figures 1A and 1B and in Figures 3A and 3B ; i.e ., diameter (y) is the greatest diameter of the 10 aneurysm to be treated or is one of the greater diameters of the 10 aneurysm so long as the 14 mesh body is oversized in such a manner so as to sufficiently seal the 22 neck of the 10 aneurysm to trigger clot formation and/or healing of the 10 aneurysm.
  • An exemplary range of the diameter (x) of the occlusion device disclosed herein is approximately 6-30 millimeters (mm) and an exemplary diameter (y) of the aneurysm to be treated is less than the value of x.
  • the diameter (x) of the occlusion device is any of 7 mm, 11 mm, and/or 14 mm.
  • the position of the 34 distal end of the substantially solid 16 marker is attached approximately equidistantly from the opposing ends of the 14 resilient mesh body. Such a positioning of the 16 marker on the intrasaccular 14 resilient mesh body confers full retrievability of the occlusion device disclosed herein.
  • the occlusion device disclosed herein is "oversized" relative to any vessel to be treated, such as, in pathological conditions in which vessel occlusion is desired, e.g , in peripheral vascular disease.
  • the diameter (x) of the occlusion device is greater than the diameter (z) of any vessel to be treated so long as the 14 body of the occlusion device is capable of conforming to vessel walls and promoting clot formation.
  • Figure 1B and Figure 3B show an embodiment of an occlusion device as disclosed herein deployed within an 10 aneurysm to be treated.
  • Figure 1B and Figure 3B show the diameter (y) of such an 10 aneurysm to be treated and also shows the blood flow (arrows) in the 12 parent vessel (and basilar artery) adjacent to the 10 aneurysm and its 22 neck.
  • the 14 resilient mesh body of the occlusion device when in free air and when deployed, is a "low profile" configuration.
  • the terminology “low profile” means that the 14 resilient mesh body, in free air, has a 32 height that is between about 10-20% of its width, and therefore in its deployed shape the 14 resilient mesh body lays flush, in a flattened manner, up against the 10 aneurysm walls and is positioned to cover at least the interior surface of the 20 lower portion of the 10 aneurysm and seal the 22 neck of the 10 aneurysm.
  • the occlusion device disclosed herein is lower and/or slimmer than occlusion devices readily available in the art which expand to fill the space of the 10 aneurysm dome (fully and/or partially with respect to the majority of the space in the 10 aneurysm) and which expand radially and/or which expand in a spherical manner.
  • the 14 resilient mesh body, in free air has a 32 height between about 12-18% of its width.
  • the 14 resilient mesh body, in free air has a 32 height between about 14-16% of its width.
  • the 14 resilient mesh body, in free air has a 32 height of about 15% of its width.
  • the deployed shape of the low profile 14 resilient mesh body covers between about 40%-80% of the inner surface area of the 10 aneurysm dome. In another embodiment, the deployed shape of the low profile 14 resilient mesh body covers between about 50%-70% of the inner surface area of the 10 aneurysm dome. In another embodiment, the deployed shape of the low profile 14 resilient mesh body covers about 60% of the inner surface area of the 10 aneurysm dome.
  • the low profile, winged shaped and/or openended expanded spread configuration of the 14 body is a single layer of resilient mesh material.
  • the low profile, expanded spread configuration is a 24 dual (or double) layer of resilient mesh material.
  • such a 14 resilient mesh body is "oversized" in comparison to the 10 aneurysm to be treated; and therefore the 14 mesh body has a diameter (x) greater than the diameter (y) of the 10 aneurysm to be treated ( i.e ., the greatest diameter or one of the greater diameters of the 10 aneurysm to be treated so long as the 14 mesh body is oversized in such a manner so as to sufficiently seal the 22 neck of the 10 aneurysm to trigger clot formation and/or healing of the 10 aneurysm).
  • the low profile and oversizing attributes of the 14 resilient mesh body confer its capabilities for conforming to the inner surface of the walls of the 10 aneurysm (via the opposing pressure of the 14 body against the 10 aneurysm walls) and therefore the occlusion device expands in only at least the 20 lower portion ( i.e ., in a low volume flattened manner) of the 10 aneurysm along the 10 aneurysm walls, thereby eliminating the need for material to pin the 22 neck of the 10 aneurysm and/or to anchor within the 12 parent vessel (and thereby minimizing the need for anti-coagulation therapy).
  • the wing-span and/or expanded spread of the 14 body conforms to the interior surface of the 10 aneurysm and apposes the 10 aneurysm dome.
  • Such a configuration facilitates sealing of the 22 neck of the 10 aneurysm and therefore clot formation and/or healing and/or shrinkage of the 10 aneurysm which is particularly advantageous if the size or mass of the 10 aneurysm is causing pain or other side effects within the patient.
  • Such a configuration is also advantageous because it requires a minimum amount of resilient mesh material thereby eliminating the need to fill or substantially fill, in a spherical, radially expanded manner, the space in the 10 aneurysm dome.
  • Such an occlusion device is well suited for conformability across a broad range of 10 aneurysm morphologies, particularly since it is well known and generally accepted that 10 aneurysms are not perfectly round in shape. It is also advantageous because an occlusion device as disclosed herein, having a "minimum of' or less material than the current standard devices, minimizes the need for anti-coagulation therapy and/or lessens the risk of clot emboli formation which could flow deeper into the vascular tree inducing stroke.
  • the single layer or 24 dual layer of resilient mesh material of the low profile device comprises a relatively uniform distribution of wire mesh strands or braids such as, without limitation, a 72 nitinol (NiTi) wire mesh strand braided configuration.
  • the occlusion device comprises wire mesh strands or braids that range from 36 to 144 NiTi strand braided configuration.
  • a 24 dual layer occlusion device disclosed herein is a configuration of wire mesh which is folded circumferentially ( 26 circumferential fold line) and therefore doubled back on itself.
  • the ends of the 24 dual or doubled back layer intersect with the 16 marker positioned approximately at the core of the 14 body of the device.
  • the device is constructed by circumferentially folding a single layer of mesh material over itself on a preferential 26 fold line effectively resulting in an occlusion device comprising a 24 dual layer of wire mesh material, i.e ., the 24 dual layer of mesh comprises a single layer of mesh folded circumferentially ( 26 circumferential fold line).
  • this 24 doubled or dual layer of wire mesh material triggers a mechanism of action believed to contribute to the enhanced acute thrombogenicity of the device in animal studies. It is believed that the localizing of a small volume of clot between the 24 dual/double layers, which have a high surface area contribution from the wire strands, facilitates nucleating and stabilizing thrombus.
  • the 14 body having a folded back 24 dual layer is deeper when compared to a non-deployed 24 dual layer occlusion device accounting for a change in width of approximately 15% which translates to an increase in the diameter (x) of the device when pressure is applied at the 16 marker.
  • This change in width/increase in diameter (x) is an effective anchoring feature of the deployed device as blood applies pressure to the mesh 14 body distributed across the 22 neck of the 10 aneurysm.
  • Such a configuration also provides sufficient apposition of the 14 body of the device against the 10 aneurysm wall or vessel wall for peripheral arterial or venous occlusion.
  • the device disclosed herein provides sufficient mesh density to confer stasis acutely. It is further known, based on analyzing the device in post-deployment that the wire mesh/braid distribution remains relatively uniform.
  • Figure 1B and Figure 4B also show the position of the 16 marker, having a 36 proximal end and a 34 distal end, on an occlusion device of the present invention.
  • the 34 distal end of the 16 marker is attached to the 14 resilient mesh body of the occlusion device.
  • the 36 proximal end of the 16 marker is shown resting across, in the manner of a bridge-like mechanism, the 22 neck of the 10 aneurysm to be treated, which when combined with the properties of the low profile 14 resilient mesh body, eliminates the need for incorporating additional material to pin the 22 neck of the 10 aneurysm and/or as an anchor within the 12 parent vessel and advantageously provides for full retrievability of the device.
  • the 16 marker of the occlusion device disclosed herein is a substantially solid collar or rigid member such as, without limitation a solid ring comprised of materials such as, without limitation, gold, platinum, stainless steel, and/or combinations thereof.
  • radiopaque materials such as, without limitation, gold, platinum, platinum/iridium alloy, and/or combinations thereof, can be used.
  • Such a 16 marker provides visualization of the device during delivery and placement. The 16 marker is positioned within the occlusion device so that the 36 proximal end of the 16 marker is capable of resting above the 22 neck of an 10 aneurysm.
  • the solidness of the 16 marker helps confer stability of the device within the 10 aneurysm and prevents movement or the transfer of forces through the resilient mesh of the 14 body thereby preventing misplacement or accidental movement of the device.
  • the 16 marker is also configured with a junction to cooperate and release from/attach to a corresponding delivery means such as, without limitation, a delivery catheter or guide wire and/or 18 pusher wire technologies. It also advantageously provides for full retrievability of the device disclosed herein.
  • the substantially solid 16 marker comprises a radiopaque material (such as for example, without limitation, platinum, gold, platinum/iridium alloy, and/or combinations thereof) to facilitate visualization of the occlusion device under fluoroscopy during delivery, placement and/or deployment.
  • the 16 marker comprises a 36 proximal end and a 34 distal end.
  • a 14 resilient mesh body is attached to the 34 distal end and the 36 proximal end of the 16 marker may be configured to influence shape, diameter, and/or curvature of the 14 resilient mesh body upon expansion of the occlusion device.
  • the 16 marker may be designed in various shapes to influence the overall profile of the occlusion device to ensure a proper fit of the expanded/deployed occlusion device within the 10 aneurysm sac.
  • Figure 2A-2C and Figure 4A-C show an exemplary means for delivery and/or deployment, through an 12 artery and/or vessel adjacent to the 10 aneurysm, of the occlusion device disclosed herein.
  • the occlusion device is delivered in a closed, compacted position (delivery shape) as shown in Figures 2A and 4A , such that the low profile 14 body is closed inward on itself or compressed, via a 18 pusher wire mechanism.
  • the ends of the low profile 14 resilient mesh body open outward in the manner of the opening of a flower (as shown in Figure 2B and Figure 4B ) and the opened 14 body then conforms to the walls of the 10 aneurysm permitting the 16 marker to rest across the 22 neck and the low profile 14 body to lay flush in a flattened manner (deployed shape) covering at least the 20 lower portion of the 10 aneurysm and sealing the 22 neck of the 10 aneurysm.
  • the device shows the deepening and/or flattening of the either the single layer ( Figure 2C ) or 24 dual layer ( Figure 4C ) device accounting for a change in width and an increase in the diameter (x) of the device when pressure is applied at the 16 marker.
  • This change in width/increase in diameter (x) is an effective anchoring feature of the deployed device as blood applies pressure to the 14 body distributed across the 22 neck of the 10 aneurysm.
  • FIG. 5A-5B show an exemplary means for electrolytic delivery and/or deployment and/or detachment of the occlusion device disclosed herein through an 12 artery and/or vessel adjacent to the 10 aneurysm.
  • Electrolytic detachment means and methods such as U.S. Patent 5,122,136 are well known in the art.
  • a 28 coil-wound core wire (or guide wire) of the catheter (or micro-catheter) is attached inside the 16 marker at its 34 distal end to the 24 dual layer occlusion device disclosed herein (as shown in Figure 5A ).
  • the coil wind maintains a constant diameter ( ⁇ ) so as not to impact upon flexibility or stiffness of the delivery catheter or micro-catheter or guide wire.
  • FEP Fluorinated Ethylene Propylene heat shrink tubing encases the 28 coil-wound portion of the core wire.
  • Numerous readily available and well known attachment techniques in the medical device arts can be used to attach the distal end of the core wire inside the 16 marker band and to the occlusion device or implant. Such attachment techniques include, without limitation, adhesives, laser melting, laser tack, spot, and/or continuous welding.
  • an adhesive is used to attach the distal end of the core wire inside the 16 marker band.
  • the adhesive is an epoxy material which is cured or hardened through the application of heat or UV (ultra-violet) radiation.
  • the epoxy is a thermal cured, two-part epoxy such as EPO-TEK® 353ND-4 available from Epoxy Technology, Inc., 14 Fortune Drive, Billerica, Mass.
  • EPO-TEK® 353ND-4 available from Epoxy Technology, Inc., 14 Fortune Drive, Billerica, Mass.
  • Such an adhesive or epoxy material encapsulates the junction of the core wire inside the marker band and increases its mechanical stability.
  • the 28 coil-wound core wire detaches the 24 dual layer occlusion device disclosed herein at an 30 electrolytic detachment site (or zone) on the core wire itself in such a manner so that the core wire is severed and/or dissolved through electrolytic action at the base of the 16 marker band (as shown in Figure 5B ). Such action then releases and/or places the 24 dual layer occlusion device into an aneurysm or vessel to be treated.
  • the low profile 14 resilient mesh body of the occlusion device disclosed herein can be filled with an embolic material to promote clotting and closure of the 10 aneurysm.
  • the oversized occlusion device disclosed herein may further incorporate adjunctive elements and/or members such as coiling techniques, framing coils, embolic agents, additional markers, polymers, resorbent polymers and/or a combination thereof.
  • Resilient mesh materials for design and/or manufacture of occlusion devices are readily available and well known by those skilled in the relevant art.
  • resilient mesh materials range from a wide variety of available materials such as, without limitation, nickel titanium (nitinol or otherwise known as NiTi), stainless steel, polymers, and/or combinations thereof.
  • Exemplary known biomedical polymeric families include, without limitation, polymers such as polyphosphazenes, polyanhydrides, polyacetals, poly(ortho esters), polyphosphoesters, polycaprolactones, polyurethanes, polylactides, polycarbonates, polyamides, and/or a combination thereof. (See, e.g., J Polym Sci B Polym Phys. Author manuscript; available in PMC 2012 June 15 .)
  • the resilient mesh material is formed of woven strands of polymer material, such as, without limitation, nylon, polypropylene or polyester.
  • the polymer strands can be filled with a radiopaque material which allows the physician treating the aneurysm to fluoroscopically visualize the location of the device within the vasculature.
  • Radiopaque filler materials preferably include bismuth trioxide, tungsten, titanium dioxide or barium sulfate, or radiopaque dyes such as iodine.
  • the resilient mesh material can be formed by strands of radiopaque material. The radiopaque strands allow the physician and/or radiologist to fluoroscopically visualize the location of the mesh, without the use of filled polymer materials.
  • radiopaque strands may be formed with materials such as, without limitation, gold, platinum, a platinum/iridium alloy, and/or a combination thereof.
  • the resilient mesh material is constructed of 10%-20% platinum core NiTi.
  • the resilient mesh material is constructed of 10% platinum core NiTi, 15% platinum core NiTi, or 20% platinum core NiTi. 10% platinum core NiTi construction is sufficient to provide a ghost image of the occlusion device under x-ray.
  • DFT® wire is a metal-to-metal composite constructed to combine the desired physical and mechanical attributes of two or more materials into a single wire.
  • the NiTi outer layer is able to provide the resulting composite wire with similar mechanical properties of a 100% NiTi wire.
  • DFT® wires are available from Fort Wayne Metals Corp., Fort Wayne, Ind., U.S.A. See also, for example, the journal article entitled Biocompatible Wire by Schaffer in Advanced Materials & Processes, Oct 2002, pages 51-54 , referenced herein.
  • the strands may be covered with a polymer coating or extrusion.
  • the coating or extrusion over the radiopaque wire strands provides fluoroscopic visualization but also increases the resistance of the strands to bending fatigue and may also increase lubricity of the strands.
  • the polymer coating or extrusion in one embodiment, is coated or treated with an agent which tends to resist clotting, such as heparin. Such clot resistant coatings are generally known.
  • the polymer coating or extrusion can be any suitable extrudable polymer, or any polymer that can be applied in a thin coating, such as Teflon® or polyurethane.
  • the strands of the resilient mesh material are formed using both metal and polymer braided strands. Combining the metal strands with the polymer strands into a braid changes the flexibility characteristics of mesh. The force required to deploy and/or collapse such a mesh portion is significantly reduced over that required for a mesh portion that includes only metal mesh strands. However, the radiopaque characteristics of the mesh for fluoroscopic visualization are retained.
  • Metal strands forming such a device includes, without limitation, stainless steel, gold, platinum, platinum/iridium, nitinol, and/or combinations thereof.
  • Polymer strands forming the device can include nylon, polypropylene, polyester, Teflon®, and/or combinations thereof.
  • polymer strands of the mesh material can be chemically modified to make them radiopaque with known techniques such as, without limitation, by using gold deposition onto the polymer strands, or by using ion beam plasma deposition of suitable metal ions onto the polymer strands.
  • the resilient mesh material can also be formed with filaments or strands of varying diameter and/or varying flexibility. By varying the size or flexibility of the polymer strands, the flexibility characteristics of the mesh, upon deployment, can also be varied. By varying the flexibility characteristics, both the deployed and collapsed configuration of the 14 resilient mesh body can be varied or changed to substantially any desired shape.
  • the mesh be formed of both polymer strands or filaments and metal strands or filaments, but it can be formed using filaments of different polymer materials.
  • different polymer materials having different flexibility characteristics can be used in forming the mesh. This alters the flexibility characteristics to change the resultant configuration of the 14 mesh body in both the deployed and the collapsed positions.
  • biomedical polymers are readily known and available in the art and can be derived from polymeric families such as, without limitation, polyphosphazenes, polyanhydrides, polyacetals, poly (ortho esters), polyphosphoesters, polycaprolactones, polyurethanes, polylactides, polycarbonates, polyamides, and/or a combination thereof.
  • Resilient mesh materials suitable for use within the 14 mesh body may take the form of a flat woven sheet, knitted sheet, or a laser cut wire mesh.
  • the material should include two or more sets of substantially parallel strands, with one set of parallel strands being at a pitch of between 45 degrees and 135 degrees with respect to the other set of parallel strands.
  • the two sets of parallel strands forming the mesh material are substantially perpendicular to each other.
  • the pitch and general construction of the mesh material may be optimized to meet the performance needs of the occlusion device.
  • the wire strands of the metal fabric used in the present invention should be formed of a material which is both resilient and can be heat-treated to substantially set a desired shape.
  • Materials which are believed to be suitable for this purpose include a cobalt-based low thermal expansion alloy referred to in the field of occlusion devices as Elgiloy®, nickel-based high-temperature high-strength "superalloys" commercially available from Haynes International under the trade name Hastelloy®, nickel-based heat treatable alloys sold under the name Incoloy® by International Nickel, and a number of different grades of stainless steel.
  • the important factor in choosing a suitable material for the wires is that the wires retain a suitable amount of the deformation induced by the molding surface (or shape memory, as described below) when subjected to a predetermined heat treatment.
  • shape memory alloys tend to have a temperature induced phase change which will cause the material to have a preferred configuration which can be fixed by heating the material above a certain transition temperature to induce a change in the phase of the material. When the alloy is cooled, the alloy will "remember" the shape it was in during the heat treatment and will tend to assume that same and/or similar configuration unless constrained from doing so.
  • NiTi alloys such as nitinol, including appropriate compositions and handling requirements, are well known in the art and such alloys need not be discussed in detail here.
  • United States Patent Numbers 5,067,489 and 4,991, 602 discuss the use of shape memory NiTi alloys in guide wire-based technologies. Such NiTi alloys are preferred, at least in part, because they are commercially available and more is known about handling such alloys than other known shape memory alloys.
  • NiTi alloys are also very elastic. Indeed, they are said to be known as “superelastic” or “pseudoelastic.” This elasticity will help an occlusion device as disclosed herein return to prior expanded configuration for deployment thereof.
  • the wire strands can comprise a standard monofilament of the selected material, i.e ., a standard wire stock may be used. In some embodiments, 72 wire strands and/or 72 strand braid configuration may be used. In other embodiments, the occlusion device comprises wire mesh strands or braids that range from 36 to 144 NiTi strand braided configurations. If so desired, though, the individual wire strands may be formed from "cables" made up of a plurality of individual wires. For example, cables formed of metal wires where several wires are helically wrapped about a central wire are commercially available and NiTi cables having an outer diameter of 0.003 inches, wherein linch equals 2.54cm, or less can be purchased. One advantage of certain cables is that they tend to be "softer" than the monofilament wires having the same diameter and formed of same material. Additionally, the use of a cable can increase the effective surface area of the wire strand, which will tend to promote thrombosis.
  • An occlusion device disclosed herein is configured with low profile resilient mesh material of a mesh density sufficient for functioning in such a manner as an endothelial cell scaffold within a vessel or across the 22 neck of the 10 aneurysm and thereby reducing blood flow by about 60% to trigger clot formation and/or healing of the 10 aneurysm.
  • mesh density means the level of porosity or the ratio of metal to open area of the 14 mesh body.
  • Mesh density relates to the number and size of the openings or pores of the mesh and by the extent that the pores are open or closed in situations where opening or pore openness varies between delivery and deployment.
  • a high mesh density region of a resilient mesh material has approximately about 40% or more metal area and about 60% or less open area.
  • the 14 resilient mesh body may be formed uniformly of the same material; however such material may have different knitted, stitched, braided, and/or cut construction.
  • the implantable occlusion device disclosed herein can be used for the process of peripheral vascular embolization (a process well known in the art and known to involve the shutdown of blood flow distal to a specified vascular point), for example, in the treatment and/or amelioration of peripheral arterial or venous pathologies and/or any related pathologies requiring vessel occlusion for the treatment thereof.
  • the occlusion device of the present invention may incorporate reasonable design parameters, features, modifications, advantages, and variations that are readily apparent to those skilled in the art in the field of occlusion devices.
  • the rabbit elastase aneurysm model is a well-accepted and art-recognized model for testing novel neurointerventional devices and has been the subject of a number of clinical publications regarding efficacy and similarity to human response. (See, e.g ., Altes et al. Creation of Saccular Aneurysms in the Rabbit: A Model Suitable for Testing Endovascular Devices. AJR 2000; 174: 349-354 .) It therefore is readily accepted by the regulatory agencies as an appropriate test model. The model's coagulation system is highly similar to that of humans.
  • the model has advantageous anatomical aspects in that the diameters of the rabbits' extra-cranial carotid arteries are highly similar to the diameter of extra-cranial carotid arteries in humans. Moreover, elastase-induced aneurysms have been shown to behave in a histologically similar manner as human aneurysms.
  • Non-detachable occlusion device lot 30680 Detachable occlusion device lot 30676, Aneurysm size 4.5 millimeters (mm) (height) x 2.5 width
  • the non-detachable occlusion device was positioned into the aneurysm with the marker at the neck of the aneurysm and contrast runs performed at timed intervals. Immediately after deployment of the device, it was observed to be in a good position in the aneurysm and there was some slowing of flow. At 5 minutes post deployment, there was some stasis observed in the aneurysm. At 10 minutes post deployment, further stagnation in the aneurysm was observed and the device was repositioned closer to the aneurysm neck. At 15 minutes post deployment, stagnation of flow in the aneurysm was observed. When the device was removed from the aneurysm and heparin was given, flow into the aneurysm returned to pre-deployment status.
  • the non-detachable occlusion device was then removed and a 7mm diameter occlusion device advanced into a 0.027" lumen microcatheter (ExcelsiorXT27, Stryker) using a 0.014" guide wire (Synchro2, Stryker). Advancement of the device in the catheter was noted to be smooth with low friction.
  • the occlusion device was advanced to the neck of the aneurysm and deployed. Timed angiographic runs were performed. Immediately post deployment, there was stasis of flow observed in the aneurysm. At 5 minutes post deployment, a filling defect in the aneurysm was observed. At 10 minutes post deployment, thrombus in the aneurysm was observed. At 20 minutes post deployment, the 5F catheter removed. On completion of the procedure the animal was euthanized in accordance with the Standard Operating Procedure (SOP).
  • SOP Standard Operating Procedure
  • Non-detachable occlusion device lot 30680 Detachable occlusion device lot 30676, Aneurysm size 10mm height x 4mm wide x 3mm neck
  • Example II A similar procedure to Example I was performed with the placement of the non-detachable device into the aneurysm neck.
  • a 4F system wherein 1Fr equals 0.33mm, was used to introduce the device into the 5F sheath and a "step" on the internal hub of the catheter was noted to cause the device to catch.
  • the device was placed and timed angiographic runs obtained as before.
  • Immediately post deployment some flow reduction was observed in the aneurysm.
  • a filling defect was observed in the aneurysm sac.
  • an increase in size of the filling defect was observed.
  • This device was removed, angiography demonstrated that flow had returned to pre-deployment status in the aneurysm, and an implantable (detached) device was deployed using the same method as previously.
  • the implant required some force initially to transition into the microcatheter from the loading sheath (possibly due to poor sheath to hub lumen compatibility) but once inserted, the microcatheter advanced freely.
  • the device was noted to have reasonable deployment control despite not being fixed to a detachment mechanism. Positioning was achieved to cover the neck of the aneurysm and timed angiographic runs obtained. Immediately post deployment, thrombosis was observed at a distal portion of the aneurysm. At 5 minutes post deployment, virtual occlusion of the aneurysm sac was observed. At 10 minutes post deployment, complete occlusion of the aneurysm sac was observed. At 15 minutes post deployment, occlusion of the aneurysm distal to the device marker was observed.
  • ACT Activated Clotting Time
  • Detachable device lot 30676 Aneurysm size 6.5 mm x 3.1 mm width x 2.4 mm neck
  • This series of angiograms confirm the wire mesh braid configuration of the occlusion device disclosed herein is sufficiently dense to reduce blood flow in the aneurysm leading to stasis of blood and thrombosis in the aneurysm sac.
  • Manipulation and deployment control of the occlusion device were carried out while visualizing the proximal radiopaque marker of the device in relation to the catheter tip.
  • Device development will entail the incorporation of radiopaque struts of platinum core NiTi wire to aid in visibility.
  • the occlusion device in the animal studies was of limited expansion (7 mm). Device development will incorporate increased diameters of greater than 7 mm. Accordingly, such devices have been designed with diameters of 11 mm and 14 mm. Even so, despite limitations with expansion spread of the 7 mm devices, all deployments promoted stasis in the aneurysms and all devices were easy to manipulate with pinpoint accuracy, particularly in relation to guidance through the parent arteries and neck of the aneurysms and placement within the aneurysms across the neck of the aneurysms.

Landscapes

  • Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pathology (AREA)
  • Surgical Instruments (AREA)

Claims (9)

  1. Dispositif d'occlusion destiné à une implantation dans le sac d'un anévrisme (10) comprenant :
    (a) un marqueur solide (16) ayant une extrémité proximale (36) et une extrémité distale (34) ; et
    (b) un corps en maillage souple (14) relié à l'extrémité distale (34) du marqueur (16), le corps en maillage souple (14) ayant une forme allongée et une forme en creux ayant une hauteur qui est comprise entre 10% et 20% de sa largeur à l'air libre, et capable de se conformer à des parois d'anévrisme ;
    ledit dispositif d'occlusion étant caractérisé en ce que le corps en maillage souple (14) est une double couche de maillage (24) qui comprend une seule couche de maillage repliée de manière circonférentielle afin de créer une ligne de pliage circonférentielle (26) autour de la circonférence du corps (14), et repliée par-dessus les extrémités du maillage souple, et dans lequel toutes les extrémités repliées de la couche double du maillage se trouvent dans le marqueur (16).
  2. Dispositif d'occlusion selon la revendication 1, dans lequel la forme déployée du corps en maillage souple en creux est capable d'être apposée contre un dôme d'anévrisme.
  3. Dispositif d'occlusion selon la revendication 1, dans lequel l'extrémité proximale (36) du marqueur (16) repose contre le collet d'anévrisme (22), ce qui élimine la nécessité d'un matériel supplémentaire pour se fixer sur le collet d'anévrisme (22).
  4. Dispositif d'occlusion selon la revendication 1, dans lequel le marqueur (16) est un marqueur radio-opaque.
  5. Dispositif d'occlusion selon la revendication 1, dans lequel le marqueur (16) est une jonction à détachement destinée à déployer le dispositif d'occlusion.
  6. Dispositif d'occlusion selon la revendication 1, dans lequel le marqueur (16) est une jonction à fixation destinée à récupérer le dispositif d'occlusion.
  7. Dispositif d'occlusion selon la revendication 1, dans lequel le marqueur (16) comprend un élément rigide.
  8. Dispositif d'occlusion selon la revendication 1, dans lequel le marqueur (16) est une bague solide.
  9. Kit de traitement et/ou d'amélioration d'un anévrisme (10), le kit comprenant :
    a. un dispositif d'occlusion destiné à une implantation dans le sac d'un anévrisme comprenant (i) un marqueur solide (16) ayant une extrémité proximale (36) et une extrémité distale (34) ; et (ii) un corps en maillage souple (14) relié à l'extrémité distale (34) du marqueur (16), le corps en maillage souple (14) ayant une forme allongée et une forme en creux ayant une hauteur comprise entre 10% et 20% de sa largeur à l'air libre, et capable de se conformer à des parois d'anévrisme ; dans lequel le corps en maillage souple (14) est une double couche de maillage (24) qui comprend une seule couche de maillage repliée de manière circonférentielle afin de créer une ligne de pliage circonférentielle autour de la circonférence du corps (14), et repliée sur les extrémités du maillage souple, et dans lequel toutes les extrémités repliées de la double couche du maillage se trouvent dans le marqueur (16) ; et
    b. un système d'accrochage ou de décrochage (18) adapté pour accrocher ou décrocher le dispositif d'occlusion.
EP15720947.9A 2014-04-30 2015-04-29 Dispositif d'occlusion Active EP3136986B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP21206876.1A EP3970635A1 (fr) 2014-04-30 2015-04-29 Appareil d'occlusion
EP19159876.2A EP3510945B1 (fr) 2014-04-30 2015-04-29 Dispositif d'occlusion

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461986369P 2014-04-30 2014-04-30
US201462083672P 2014-11-24 2014-11-24
PCT/EP2015/059429 WO2015166013A1 (fr) 2014-04-30 2015-04-29 Dispositif d'occlusion

Related Child Applications (3)

Application Number Title Priority Date Filing Date
EP19159876.2A Division EP3510945B1 (fr) 2014-04-30 2015-04-29 Dispositif d'occlusion
EP19159876.2A Division-Into EP3510945B1 (fr) 2014-04-30 2015-04-29 Dispositif d'occlusion
EP21206876.1A Division EP3970635A1 (fr) 2014-04-30 2015-04-29 Appareil d'occlusion

Publications (2)

Publication Number Publication Date
EP3136986A1 EP3136986A1 (fr) 2017-03-08
EP3136986B1 true EP3136986B1 (fr) 2019-04-17

Family

ID=53055025

Family Applications (3)

Application Number Title Priority Date Filing Date
EP21206876.1A Pending EP3970635A1 (fr) 2014-04-30 2015-04-29 Appareil d'occlusion
EP19159876.2A Active EP3510945B1 (fr) 2014-04-30 2015-04-29 Dispositif d'occlusion
EP15720947.9A Active EP3136986B1 (fr) 2014-04-30 2015-04-29 Dispositif d'occlusion

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP21206876.1A Pending EP3970635A1 (fr) 2014-04-30 2015-04-29 Appareil d'occlusion
EP19159876.2A Active EP3510945B1 (fr) 2014-04-30 2015-04-29 Dispositif d'occlusion

Country Status (9)

Country Link
US (6) US10130372B2 (fr)
EP (3) EP3970635A1 (fr)
JP (5) JP6571760B2 (fr)
CN (1) CN106456183B (fr)
CA (1) CA2946078C (fr)
ES (2) ES2732752T3 (fr)
IL (1) IL248515A0 (fr)
MX (2) MX381828B (fr)
WO (1) WO2015166013A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4106670A2 (fr) * 2020-02-20 2022-12-28 Cerus Endovascular Limited Méthodes de protection distale d'élimination de caillots

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11471163B2 (en) 2008-05-01 2022-10-18 Aneuclose Llc Intrasaccular aneurysm occlusion device with net or mesh expanded by string-of-pearls embolies
US11583289B2 (en) 2008-05-01 2023-02-21 Aneuclose Llc Aneurysm-occluding mesh ribbon with a series of loops or segments having distal-to-proximal variation in size, shape, and/or orientation
US11484322B2 (en) 2018-01-03 2022-11-01 Aneuclose Llc Aneurysm neck bridge with a closeable opening or lumen through which embolic material is inserted into the aneurysm sac
US12004750B2 (en) 2008-05-01 2024-06-11 Aneuclose Llc Methods for creating an expandable two-part intrasacular aneurysm occlusion device from a tubular mesh
US11471164B2 (en) 2008-05-01 2022-10-18 Aneuclose Llc Methods of occluding a cerebral aneurysm by inserting embolic members or material into an intrasacular implant
US11357511B2 (en) 2008-05-01 2022-06-14 Aneuclose Llc Intrasacular aneurysm occlusion device with globular first configuration and bowl-shaped second configuration
US10716573B2 (en) 2008-05-01 2020-07-21 Aneuclose Janjua aneurysm net with a resilient neck-bridging portion for occluding a cerebral aneurysm
US11464518B2 (en) 2008-05-01 2022-10-11 Aneuclose Llc Proximal concave neck bridge with central lumen and distal net for occluding cerebral aneurysms
WO2009135166A2 (fr) 2008-05-02 2009-11-05 Sequent Medical Inc. Dispositifs filamentaires pour le traitement de défauts vasculaires
US20140135811A1 (en) 2012-11-13 2014-05-15 Covidien Lp Occlusive devices
US9526503B2 (en) * 2013-08-12 2016-12-27 W. L. Gore & Associates, Inc. Lumbar ostia occlusion devices and methods of deploying the same
US9955976B2 (en) 2013-08-16 2018-05-01 Sequent Medical, Inc. Filamentary devices for treatment of vascular defects
US11076860B2 (en) 2014-03-31 2021-08-03 DePuy Synthes Products, Inc. Aneurysm occlusion device
US11154302B2 (en) 2014-03-31 2021-10-26 DePuy Synthes Products, Inc. Aneurysm occlusion device
MX381828B (es) 2014-04-30 2025-03-13 Cerus Endovascular Ltd Dispositivo de oclusión.
US11484319B2 (en) 2015-01-20 2022-11-01 Neurogami Medical, Inc. Delivery system for micrograft for treating intracranial aneurysms
US10736730B2 (en) 2015-01-20 2020-08-11 Neurogami Medical, Inc. Vascular implant
WO2016118420A1 (fr) 2015-01-20 2016-07-28 Neurogami Medical, Inc. Microgreffe pour le traitement d'anévrismes intracrâniens et procédé d'utilisation
US10925611B2 (en) 2015-01-20 2021-02-23 Neurogami Medical, Inc. Packaging for surgical implant
US10857012B2 (en) 2015-01-20 2020-12-08 Neurogami Medical, Inc. Vascular implant
CA2976260C (fr) 2015-02-25 2024-02-06 Galaxy Therapeutics, Llc Systeme et procede pour traiter les anevrismes
US10548579B2 (en) * 2015-07-29 2020-02-04 Cardiac Pacemakers, Inc. Left atrial appendage implant
CA3005686A1 (fr) 2015-12-07 2017-06-15 Cerus Endovascular Limited Dispositif d'occlusion
ES3039667T3 (en) 2015-12-18 2025-10-23 Stryker Corp Vaso-occlusive device and delivery assembly
CA3014316C (fr) * 2016-02-10 2025-08-12 Microvention, Inc. Dispositifs pour occlusion vasculaire
WO2017153603A1 (fr) 2016-03-11 2017-09-14 Cerus Endovascular Limited Dispositif d'occlusion
EP3463109A4 (fr) 2016-05-26 2020-01-08 Nanostructures, Inc. Système et procédés d'occlusion embolisée d'anévrismes neurovasculaires
WO2017214431A2 (fr) 2016-06-10 2017-12-14 Stryker Corporation Dispositifs médicaux tressés
US10576099B2 (en) 2016-10-21 2020-03-03 Covidien Lp Injectable scaffold for treatment of intracranial aneurysms and related technology
CA3054556A1 (fr) 2017-02-23 2018-08-30 DePuy Synthes Products, Inc. Dispositif pour anevrisme et systeme d'administration
US10835259B2 (en) * 2017-03-13 2020-11-17 Boston Scientific Scimed, Inc. Occlusive medical device system
CA3073232C (fr) 2017-08-21 2023-08-29 Cerus Endovascular Limited Dispositif d'occlusion
US10675036B2 (en) * 2017-08-22 2020-06-09 Covidien Lp Devices, systems, and methods for the treatment of vascular defects
US10751065B2 (en) * 2017-12-22 2020-08-25 DePuy Synthes Products, Inc. Aneurysm device and delivery system
US11185335B2 (en) * 2018-01-19 2021-11-30 Galaxy Therapeutics Inc. System for and method of treating aneurysms
US10905430B2 (en) 2018-01-24 2021-02-02 DePuy Synthes Products, Inc. Aneurysm device and delivery system
EP3745965B1 (fr) 2018-01-31 2025-01-01 Nanostructures, Inc. Dispositifs d'occlusion vasculaire utilisant des feuilles de nitinol à film mince
EP3773251A1 (fr) 2018-04-10 2021-02-17 Medstar Health Dispositifs d'échafaudage d'embolisation
US11058430B2 (en) 2018-05-25 2021-07-13 DePuy Synthes Products, Inc. Aneurysm device and delivery system
US11596412B2 (en) 2018-05-25 2023-03-07 DePuy Synthes Products, Inc. Aneurysm device and delivery system
US10939915B2 (en) 2018-05-31 2021-03-09 DePuy Synthes Products, Inc. Aneurysm device and delivery system
US11051825B2 (en) 2018-08-08 2021-07-06 DePuy Synthes Products, Inc. Delivery system for embolic braid
IL269005A (en) * 2018-09-12 2019-10-31 Depuy Synthes Products Inc Improved aneurysm occlusion device
US12064364B2 (en) 2018-09-18 2024-08-20 Nanostructures, Inc. Catheter based methods and devices for obstructive blood flow restriction
US11123077B2 (en) 2018-09-25 2021-09-21 DePuy Synthes Products, Inc. Intrasaccular device positioning and deployment system
US11076861B2 (en) * 2018-10-12 2021-08-03 DePuy Synthes Products, Inc. Folded aneurysm treatment device and delivery method
US11406392B2 (en) 2018-12-12 2022-08-09 DePuy Synthes Products, Inc. Aneurysm occluding device for use with coagulating agents
CN111388043A (zh) 2018-12-17 2020-07-10 柯惠有限合伙公司 闭塞装置
US11272939B2 (en) 2018-12-18 2022-03-15 DePuy Synthes Products, Inc. Intrasaccular flow diverter for treating cerebral aneurysms
CN109745094B (zh) * 2018-12-29 2021-09-03 先健科技(深圳)有限公司 封堵装置
EP3911253A4 (fr) * 2019-01-18 2022-03-09 Neurogami Medical, Inc. Implant vasculaire
US11134953B2 (en) 2019-02-06 2021-10-05 DePuy Synthes Products, Inc. Adhesive cover occluding device for aneurysm treatment
JP7469323B2 (ja) 2019-03-15 2024-04-16 マイクロベンション インコーポレイテッド 血管障害の治療のためのフィラメント状デバイス
US11337706B2 (en) 2019-03-27 2022-05-24 DePuy Synthes Products, Inc. Aneurysm treatment device
CN109965930B (zh) * 2019-04-29 2024-05-31 北京久事神康医疗科技有限公司 一种动脉瘤栓塞装置及动脉瘤栓塞系统
US12446886B2 (en) 2019-05-21 2025-10-21 DePuy Synthes Products, Inc. Semispherical braided aneurysm treatment system and method
US11497504B2 (en) 2019-05-21 2022-11-15 DePuy Synthes Products, Inc. Aneurysm treatment with pushable implanted braid
US11413046B2 (en) 2019-05-21 2022-08-16 DePuy Synthes Products, Inc. Layered braided aneurysm treatment device
US11672542B2 (en) 2019-05-21 2023-06-13 DePuy Synthes Products, Inc. Aneurysm treatment with pushable ball segment
US10653425B1 (en) 2019-05-21 2020-05-19 DePuy Synthes Products, Inc. Layered braided aneurysm treatment device
US11278292B2 (en) 2019-05-21 2022-03-22 DePuy Synthes Products, Inc. Inverting braided aneurysm treatment system and method
US11602350B2 (en) 2019-12-05 2023-03-14 DePuy Synthes Products, Inc. Intrasaccular inverting braid with highly flexible fill material
US11607226B2 (en) 2019-05-21 2023-03-21 DePuy Synthes Products, Inc. Layered braided aneurysm treatment device with corrugations
KR20200134171A (ko) * 2019-05-21 2020-12-01 디퍼이 신테스 프로덕츠, 인코포레이티드 층상의 편조 동맥류 치료 디바이스
US11058431B2 (en) * 2019-05-25 2021-07-13 Galaxy Therapeutics, Inc. Systems and methods for treating aneurysms
US12102327B2 (en) 2019-05-25 2024-10-01 Galaxy Therapeutics, Inc. Systems and methods for treating aneurysms
WO2021011694A1 (fr) 2019-07-17 2021-01-21 Boston Scientific Scimed, Inc. Implant d'appendice auriculaire gauche à revêtement continu
EP3771437A1 (fr) * 2019-07-29 2021-02-03 Université de Montpellier Dispositif intra-anévrismal
WO2021041831A1 (fr) 2019-08-30 2021-03-04 Boston Scientific Scimed, Inc. Implant d'appendice auriculaire gauche ayant un disque d'étanchéité
WO2021092618A1 (fr) 2019-11-04 2021-05-14 Covidien Lp Dispositifs, systèmes et procédés pour le traitement d'anévrismes intracrâniens
US11457926B2 (en) 2019-12-18 2022-10-04 DePuy Synthes Products, Inc. Implant having an intrasaccular section and intravascular section
US20210282789A1 (en) 2020-03-11 2021-09-16 Microvention, Inc. Multiple layer devices for treatment of vascular defects
US12070220B2 (en) 2020-03-11 2024-08-27 Microvention, Inc. Devices having multiple permeable shells for treatment of vascular defects
US12023034B2 (en) 2020-03-11 2024-07-02 Microvention, Inc. Devices for treatment of vascular defects
WO2021195085A1 (fr) 2020-03-24 2021-09-30 Boston Scientific Scimed, Inc. Système médical pour le traitement d'un appendice auriculaire gauche
US11931041B2 (en) 2020-05-12 2024-03-19 Covidien Lp Devices, systems, and methods for the treatment of vascular defects
JP7627761B2 (ja) 2020-11-30 2025-02-06 ボストン サイエンティフィック サイムド，インコーポレイテッド 植込型受動式平均圧センサ
WO2022149141A1 (fr) 2021-01-10 2022-07-14 Luseed Vascular Ltd. Dispositif intravasculaire
CN116669639A (zh) 2021-01-14 2023-08-29 波士顿科学医学有限公司 用于治疗左心耳的医疗系统
EP4284263A4 (fr) 2021-01-27 2024-06-26 Galaxy Therapeutics, Inc. Systèmes et méthodes pour traiter des anévrismes
US12383201B2 (en) 2021-02-03 2025-08-12 Boston Scientific Scimed, Inc. Medical system for treating a left atrial appendage
CN113017950A (zh) * 2021-02-08 2021-06-25 北京联合大学 半球形编织支架及其制作方法
WO2022198208A1 (fr) 2021-03-16 2022-09-22 Covidien Lp Compositions biopolymères injectables et systèmes et procédés associés
CN113069168B (zh) * 2021-04-07 2024-01-23 上海微密医疗科技有限公司 动脉瘤封堵装置
CN113069170A (zh) * 2021-04-30 2021-07-06 上海暖阳医疗器械有限公司 一种动脉瘤闭塞装置
CN113274087B (zh) * 2021-05-24 2022-08-26 北京泰杰伟业科技有限公司 一种瘤内扰流装置
WO2022271832A1 (fr) 2021-06-22 2022-12-29 Boston Scientific Scimed, Inc. Implant d'appendice auriculaire gauche
US12383278B2 (en) 2021-07-08 2025-08-12 Boston Scientific Scimed, Inc. Left atrial appendage closure device
US12446891B2 (en) 2021-08-30 2025-10-21 Microvention, Inc. Devices for treatment of vascular defects
EP4398815A1 (fr) 2021-09-08 2024-07-17 Boston Scientific Scimed, Inc. Implant occlusif ayant des ancrages de tissu mou à pointe fendue multi-tranchant
CN113855141A (zh) * 2021-09-28 2021-12-31 北京泰杰伟业科技有限公司 一种瘤颈封堵装置
CN113796911A (zh) * 2021-10-09 2021-12-17 上海励楷科技有限公司 分叉部动脉瘤闭塞装置
CN113951964B (zh) * 2021-11-05 2023-11-17 聚辉医疗科技(深圳)有限公司 栓塞弹簧圈和弹簧圈系统
CN114129217A (zh) * 2021-12-31 2022-03-04 江苏暖阳医疗器械有限公司 一种覆膜的动脉瘤瘤内闭塞装置
US12070221B2 (en) * 2022-07-30 2024-08-27 Covidien Lp Devices, systems, and methods for treating aneurysms
CN115607221B (zh) * 2022-12-19 2023-03-03 上海微密医疗科技有限公司 一种动脉瘤瘤内封堵装置及动脉瘤瘤内封堵系统
WO2025260020A1 (fr) * 2024-06-14 2025-12-18 Stryker Corporation Dispositifs, systèmes et procédés d'occlusion d'un anévrisme

Family Cites Families (322)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4991A (en) 1847-02-27 bagley
US602A (en) 1838-02-15 Inclined elevating box-wheel fob excavating eakth
US2849002A (en) 1956-03-12 1958-08-26 Vincent J Oddo Haemostatic catheter
US3480017A (en) 1966-04-27 1969-11-25 Wallace B Shute Cervical dilator
US4395806A (en) 1980-05-08 1983-08-02 Sorenson Research Co., Inc. Method of manufacturing a detachable balloon catheter assembly
US4364392A (en) 1980-12-04 1982-12-21 Wisconsin Alumni Research Foundation Detachable balloon catheter
US4545367A (en) 1982-07-16 1985-10-08 Cordis Corporation Detachable balloon catheter and method of use
DE3750480T2 (de) 1986-11-29 1995-03-02 Terumo Corp Mit ballon versehener katheter.
US4836204A (en) 1987-07-06 1989-06-06 Landymore Roderick W Method for effecting closure of a perforation in the septum of the heart
US5067489A (en) 1988-08-16 1991-11-26 Flexmedics Corporation Flexible guide with safety tip
JP2656818B2 (ja) 1988-12-02 1997-09-24 三井東圧化学株式会社 接着性ポリプロピレン組成物
FR2641692A1 (fr) 1989-01-17 1990-07-20 Nippon Zeon Co Bouchon de fermeture d'une breche pour application medicale et dispositif pour bouchon de fermeture l'utilisant
US4991602A (en) 1989-06-27 1991-02-12 Flexmedics Corporation Flexible guide wire with safety tip
US5065772A (en) 1989-10-13 1991-11-19 Inamed Corporation Inflatable cerivical pessary
US5122136A (en) 1990-03-13 1992-06-16 The Regents Of The University Of California Endovascular electrolytically detachable guidewire tip for the electroformation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
US6425893B1 (en) 1990-03-13 2002-07-30 The Regents Of The University Of California Method and apparatus for fast electrolytic detachment of an implant
US5221261A (en) 1990-04-12 1993-06-22 Schneider (Usa) Inc. Radially expandable fixation member
JPH0447415A (ja) 1990-06-14 1992-02-17 Amada Co Ltd ワーク搬送ロボットにおけるリニアモータの制御方法及びその装置
JPH0546421Y2 (fr) * 1990-08-23 1993-12-06
US5025060A (en) 1990-10-15 1991-06-18 Kansai Paint Co., Ltd. Dispersion of fine particles of a polymer
CA2079417C (fr) 1991-10-28 2003-01-07 Lilip Lau Empreintes extensibles et leur methode de fabrication
US5342387A (en) 1992-06-18 1994-08-30 American Biomed, Inc. Artificial support for a blood vessel
JP3001637B2 (ja) 1993-04-09 2000-01-24 ビスケイス コーポレイション チーズ用の包装容器、フィルム、袋、並びにｃｏ▲下２▼呼気性食品の包装方法
US5624449A (en) 1993-11-03 1997-04-29 Target Therapeutics Electrolytically severable joint for endovascular embolic devices
US5423829A (en) 1993-11-03 1995-06-13 Target Therapeutics, Inc. Electrolytically severable joint for endovascular embolic devices
CA2194671A1 (fr) 1994-07-08 1996-01-25 Ev3 Inc. Procede de fabrication de dispositifs medicaux, et dispositifs d'occlusion intravasculaire
US5846261A (en) 1994-07-08 1998-12-08 Aga Medical Corp. Percutaneous catheter directed occlusion devices
IL116561A0 (en) 1994-12-30 1996-03-31 Target Therapeutics Inc Severable joint for detachable devices placed within the body
US5634936A (en) 1995-02-06 1997-06-03 Scimed Life Systems, Inc. Device for closing a septal defect
RU2157146C2 (ru) 1995-06-13 2000-10-10 ВИЛЬЯМ КУК Европа, A/S Устройство для имплантации в сосудах и полых органах (его варианты)
US6168622B1 (en) 1996-01-24 2001-01-02 Microvena Corporation Method and apparatus for occluding aneurysms
US5733294A (en) 1996-02-28 1998-03-31 B. Braun Medical, Inc. Self expanding cardiovascular occlusion device, method of using and method of making the same
US5853422A (en) 1996-03-22 1998-12-29 Scimed Life Systems, Inc. Apparatus and method for closing a septal defect
US6949116B2 (en) 1996-05-08 2005-09-27 Carag Ag Device for plugging an opening such as in a wall of a hollow or tubular organ including biodegradable elements
DK177010B1 (da) 1996-09-03 2010-11-29 Cook William Europ Embolisationsindretning til placering i et blodkar
US6254628B1 (en) 1996-12-09 2001-07-03 Micro Therapeutics, Inc. Intracranial stent
US6007573A (en) 1996-09-18 1999-12-28 Microtherapeutics, Inc. Intracranial stent and method of use
US20010041900A1 (en) 1999-12-21 2001-11-15 Ovion, Inc. Occluding device and method of use
US5928260A (en) 1997-07-10 1999-07-27 Scimed Life Systems, Inc. Removable occlusion system for aneurysm neck
US7569066B2 (en) 1997-07-10 2009-08-04 Boston Scientific Scimed, Inc. Methods and devices for the treatment of aneurysms
JP4127960B2 (ja) 1997-08-05 2008-07-30 ボストン サイエンティフィック リミテッド 着脱可能な動脈瘤頸部ブリッジ
GB9716497D0 (en) 1997-08-05 1997-10-08 Bridport Gundry Plc Occlusion device
US20100030256A1 (en) 1997-11-12 2010-02-04 Genesis Technologies Llc Medical Devices and Methods
US9498604B2 (en) 1997-11-12 2016-11-22 Genesis Technologies Llc Medical device and method
ATE404123T1 (de) 1997-11-12 2008-08-15 Genesis Technologies Llc Vorrichtung zum entfernen von okklusionen in biologischen durchgängen
WO1999039649A1 (fr) 1998-02-10 1999-08-12 Dubrul William R Appareil d'occlusion, d'ancrage et de mise en tension flottant et procedes d'utilisation
US5925060A (en) 1998-03-13 1999-07-20 B. Braun Celsa Covered self-expanding vascular occlusion device
US6096021A (en) 1998-03-30 2000-08-01 The University Of Virginia Patent Foundation Flow arrest, double balloon technique for occluding aneurysms or blood vessels
SE514546C2 (sv) 1998-05-18 2001-03-12 Allgon Ab Ett antennsystem och en radiokommunikationsanordning innefattande ett antennsystem
US6463317B1 (en) 1998-05-19 2002-10-08 Regents Of The University Of Minnesota Device and method for the endovascular treatment of aneurysms
US6113609A (en) 1998-05-26 2000-09-05 Scimed Life Systems, Inc. Implantable tissue fastener and system for treating gastroesophageal reflux disease
JP4741728B2 (ja) 1998-06-04 2011-08-10 ニューヨーク・ユニバーシティ 血管内薄膜デバイスおよびストロークの予防治療法
US6096175A (en) 1998-07-17 2000-08-01 Micro Therapeutics, Inc. Thin film stent
AU5905599A (en) 1998-09-04 2000-03-27 Boston Scientific Limited Detachable aneurysm neck closure patch
US7410482B2 (en) * 1998-09-04 2008-08-12 Boston Scientific-Scimed, Inc. Detachable aneurysm neck bridge
US7044134B2 (en) 1999-11-08 2006-05-16 Ev3 Sunnyvale, Inc Method of implanting a device in the left atrial appendage
US6152144A (en) 1998-11-06 2000-11-28 Appriva Medical, Inc. Method and device for left atrial appendage occlusion
US7128073B1 (en) 1998-11-06 2006-10-31 Ev3 Endovascular, Inc. Method and device for left atrial appendage occlusion
US6080183A (en) 1998-11-24 2000-06-27 Embol-X, Inc. Sutureless vessel plug and methods of use
EP1582178B1 (fr) 1999-02-01 2012-09-26 Board Of Regents, The University Of Texas System Dispositifs intravasculaires tissés et procédés de fabrication desdits dispositifs
US6375668B1 (en) 1999-06-02 2002-04-23 Hanson S. Gifford Devices and methods for treating vascular malformations
US20020169473A1 (en) 1999-06-02 2002-11-14 Concentric Medical, Inc. Devices and methods for treating vascular malformations
US6168579B1 (en) 1999-08-04 2001-01-02 Scimed Life Systems, Inc. Filter flush system and methods of use
US6551303B1 (en) 1999-10-27 2003-04-22 Atritech, Inc. Barrier device for ostium of left atrial appendage
US6689150B1 (en) 1999-10-27 2004-02-10 Atritech, Inc. Filter apparatus for ostium of left atrial appendage
US6994092B2 (en) 1999-11-08 2006-02-07 Ev3 Sunnyvale, Inc. Device for containing embolic material in the LAA having a plurality of tissue retention structures
US6855154B2 (en) 2000-08-11 2005-02-15 University Of Louisville Research Foundation, Inc. Endovascular aneurysm treatment device and method
EP1399213A4 (fr) 2000-10-11 2008-03-19 Micro Therapeutics Inc Methodes de traitement d'anevrismes
US6589265B1 (en) 2000-10-31 2003-07-08 Endovascular Technologies, Inc. Intrasaccular embolic device
TW491214U (en) 2000-12-12 2002-06-11 Pei-Shiou Huang Improved shelf for soft drinks
US6547804B2 (en) 2000-12-27 2003-04-15 Scimed Life Systems, Inc. Selectively permeable highly distensible occlusion balloon
US6866677B2 (en) 2001-04-03 2005-03-15 Medtronic Ave, Inc. Temporary intraluminal filter guidewire and methods of use
US20020188314A1 (en) * 2001-06-07 2002-12-12 Microvena Corporation Radiopaque distal embolic protection device
US6454780B1 (en) 2001-06-21 2002-09-24 Scimed Life Systems, Inc. Aneurysm neck obstruction device
US20030181927A1 (en) 2001-06-21 2003-09-25 Wallace Michael P. Aneurysm neck obstruction device
US8715312B2 (en) 2001-07-20 2014-05-06 Microvention, Inc. Aneurysm treatment device and method of use
US7572288B2 (en) 2001-07-20 2009-08-11 Microvention, Inc. Aneurysm treatment device and method of use
US8252040B2 (en) 2001-07-20 2012-08-28 Microvention, Inc. Aneurysm treatment device and method of use
US20030028209A1 (en) 2001-07-31 2003-02-06 Clifford Teoh Expandable body cavity liner device
US6811560B2 (en) * 2001-09-20 2004-11-02 Cordis Neurovascular, Inc. Stent aneurysm embolization method and device
JP2003190175A (ja) 2001-11-15 2003-07-08 Cordis Neurovascular Inc 動脈瘤を密閉するための動脈瘤頚部プラグ
US6773448B2 (en) 2002-03-08 2004-08-10 Ev3 Inc. Distal protection devices having controllable wire motion
US20030176884A1 (en) * 2002-03-12 2003-09-18 Marwane Berrada Everted filter device
US7695488B2 (en) 2002-03-27 2010-04-13 Boston Scientific Scimed, Inc. Expandable body cavity liner device
US20030195553A1 (en) 2002-04-12 2003-10-16 Scimed Life Systems, Inc. System and method for retaining vaso-occlusive devices within an aneurysm
US6833003B2 (en) 2002-06-24 2004-12-21 Cordis Neurovascular Expandable stent and delivery system
US20050119684A1 (en) 2002-07-12 2005-06-02 Guterman Lee R. Aneurysm buttress arrangement
US20040172056A1 (en) 2002-07-12 2004-09-02 Guterman Lee R. Bifurcated aneurysm buttress arrangement
CA2495562A1 (fr) 2002-08-05 2004-02-12 Steven J. Rychnovsky Catheter d'apport de lumiere
US20040044391A1 (en) * 2002-08-29 2004-03-04 Stephen Porter Device for closure of a vascular defect and method of treating the same
US8075585B2 (en) 2002-08-29 2011-12-13 Stryker Corporation Device and method for treatment of a vascular defect
JP2006521907A (ja) 2002-10-23 2006-09-28 ザ バイオメリックス コーポレーション 動脈瘤処置デバイスおよび方法
US7229454B2 (en) 2003-01-07 2007-06-12 Boston Scientific Scimed, Inc. Occlusive cinching devices and methods of use
US20040254594A1 (en) 2003-01-24 2004-12-16 Arthur Alfaro Cardiac defect occlusion device
US20040193246A1 (en) 2003-03-25 2004-09-30 Microvention, Inc. Methods and apparatus for treating aneurysms and other vascular defects
US7293562B2 (en) 2003-03-27 2007-11-13 Cierra, Inc. Energy based devices and methods for treatment of anatomic tissue defects
US7597704B2 (en) 2003-04-28 2009-10-06 Atritech, Inc. Left atrial appendage occlusion device with active expansion
CN101193623A (zh) 2003-05-15 2008-06-04 柏尔迈瑞克斯公司 可植入的网状弹性基质的制造和应用
US7093527B2 (en) 2003-06-10 2006-08-22 Surpass Medical Ltd. Method and apparatus for making intraluminal implants and construction particularly useful in such method and apparatus
JP4242749B2 (ja) 2003-06-19 2009-03-25 株式会社クレハ 深絞り成形用共押出積層フィルム
US7735493B2 (en) 2003-08-15 2010-06-15 Atritech, Inc. System and method for delivering a left atrial appendage containment device
DE10338702B9 (de) 2003-08-22 2007-04-26 Occlutech Gmbh Occlusioninstrument
US7232461B2 (en) 2003-10-29 2007-06-19 Cordis Neurovascular, Inc. Neck covering device for an aneurysm
US8777974B2 (en) 2004-03-19 2014-07-15 Aga Medical Corporation Multi-layer braided structures for occluding vascular defects
US9039724B2 (en) 2004-03-19 2015-05-26 Aga Medical Corporation Device for occluding vascular defects
US8747453B2 (en) 2008-02-18 2014-06-10 Aga Medical Corporation Stent/stent graft for reinforcement of vascular abnormalities and associated method
US20050228434A1 (en) 2004-03-19 2005-10-13 Aga Medical Corporation Multi-layer braided structures for occluding vascular defects
US8500751B2 (en) 2004-03-31 2013-08-06 Merlin Md Pte Ltd Medical device
CA2595809A1 (fr) 2004-08-31 2006-03-09 Cook Incorporated Dispositif de traitement d'anevrisme
US7244270B2 (en) 2004-09-16 2007-07-17 Evera Medical Systems and devices for soft tissue augmentation
USRE46662E1 (en) * 2004-09-17 2018-01-09 DePuy Synthes Products, Inc. Vascular occlusion device with an embolic mesh ribbon
EP1789123A4 (fr) 2004-09-17 2010-03-03 Cordis Neurovascular Inc Dispositifs metalliques a couche mince utilises pour colmater des anevrismes ou des vaisseaux
WO2006034153A2 (fr) 2004-09-17 2006-03-30 Cordis Neurovascular, Inc. Dispositifs metalliques a film mince pour l'obturation d'anevrismes ou de vaisseaux
CA2581272A1 (fr) * 2004-09-22 2006-05-18 Lee R. Guterman Systeme de traitement d'anevrisme cranien
US20060116713A1 (en) 2004-11-26 2006-06-01 Ivan Sepetka Aneurysm treatment devices and methods
US20090297582A1 (en) 2004-11-26 2009-12-03 Biomerix Corporation Vascular occlusion devices and methods
US20060116709A1 (en) 2004-11-26 2006-06-01 Ivan Sepetka Aneurysm treatment devices and methods
US8771294B2 (en) 2004-11-26 2014-07-08 Biomerix Corporation Aneurysm treatment devices and methods
US9545300B2 (en) 2004-12-22 2017-01-17 W. L. Gore & Associates, Inc. Filament-wound implantable devices
US20060155323A1 (en) 2005-01-07 2006-07-13 Porter Stephen C Intra-aneurysm devices
US20060155367A1 (en) 2005-01-07 2006-07-13 Hines Richard A Micro-pleated stent assembly
WO2006078988A2 (fr) 2005-01-21 2006-07-27 Loubert Suddaby Appareil et procede de reparation d'anevrisme
CN100389732C (zh) 2005-01-28 2008-05-28 先健科技(深圳)有限公司 具有自我调节功能的心脏间隔缺损封堵器
US20060206199A1 (en) 2005-03-12 2006-09-14 Churchwell Stacey D Aneurysm treatment devices
JP4576328B2 (ja) 2005-12-14 2010-11-04 株式会社リコー ファクシミリ装置
WO2007076480A2 (fr) 2005-12-23 2007-07-05 Levy Elad I Agencement destine a traiter un anevrisme
WO2007079402A2 (fr) 2005-12-31 2007-07-12 Levy Elad I Endoprothese permettant de traiter un anevrisme d'embranchement pourvue d'une toile distale
US7744652B2 (en) 2006-01-23 2010-06-29 Hesham Morsi Aneurysm sealing device
CN101049266B (zh) * 2006-04-03 2010-11-17 孟坚 医疗用闭塞器械及其制造方法
WO2007105217A2 (fr) 2006-03-14 2007-09-20 Thermopeutix Inc. Système de délivrance de spirales de traitement d'anévrismes
DE102006013770A1 (de) 2006-03-24 2007-09-27 Occlutech Gmbh Occlusionsinstrument und Verfahren zu dessen Herstellung
WO2008051279A1 (fr) 2006-03-24 2008-05-02 Biomerix Corp Dispositif endovasculaire auto-expansible pour occlusion d'anévrismes
US20120150147A1 (en) 2010-12-08 2012-06-14 Penumbra, Inc. System and method for treating ischemic stroke
US9615832B2 (en) 2006-04-07 2017-04-11 Penumbra, Inc. Aneurysm occlusion system and method
WO2007134266A2 (fr) 2006-05-12 2007-11-22 Electroformed Stents, Inc. Dispositif d'exclusion et système d'apport
DE102006036844B3 (de) 2006-08-07 2008-01-03 Kuhne Anlagenbau Gmbh Mehrschichtige flächen- oder schlauchförmige Nahrungsmittelhülle oder -folie
EP2056747A2 (fr) 2006-08-17 2009-05-13 NFOCUS Neuromedical Inc. Dispositifs d'isolement pour le traitement des anévrismes
US20080097401A1 (en) 2006-09-22 2008-04-24 Trapp Benjamin M Cerebral vasculature device
JP5148094B2 (ja) 2006-09-27 2013-02-20 株式会社東芝 超音波診断装置、医用画像処理装置及びプログラム
WO2008063455A1 (fr) 2006-11-13 2008-05-29 Hines Richard A Dispositif d'exclusion et système d'apport sur fil
EP1923019B1 (fr) 2006-11-20 2010-10-20 SeptRx, Inc. Dispositif d'empêchement le debit de l'embolie non souhaité entre veines et artères
EP2460476B1 (fr) 2007-04-16 2020-11-25 Occlutech Holding AG Dispositif d'occlusion destiné à fermer une oreillette cardiaque et son procédé de fabrication
WO2008144587A2 (fr) 2007-05-18 2008-11-27 Boston Scientific Scimed, Inc. Systèmes de détachement d'implant médical
US20110022149A1 (en) 2007-06-04 2011-01-27 Cox Brian J Methods and devices for treatment of vascular defects
US8034061B2 (en) 2007-07-12 2011-10-11 Aga Medical Corporation Percutaneous catheter directed intravascular occlusion devices
US8361138B2 (en) 2007-07-25 2013-01-29 Aga Medical Corporation Braided occlusion device having repeating expanded volume segments separated by articulation segments
EP3677192B1 (fr) 2007-08-02 2024-04-24 OCCLUTECH GmbH Dispositif médical implantable
WO2009036219A1 (fr) 2007-09-11 2009-03-19 Nfocus Neuromedical Inc. Dispositif de coiffe d'anévrisme pour l'implantation et la retenue d'agents emboliques
US20090082803A1 (en) 2007-09-26 2009-03-26 Aga Medical Corporation Braided vascular devices having no end clamps
US9414842B2 (en) 2007-10-12 2016-08-16 St. Jude Medical, Cardiology Division, Inc. Multi-component vascular device
US8926680B2 (en) 2007-11-12 2015-01-06 Covidien Lp Aneurysm neck bridging processes with revascularization systems methods and products thereby
US9220522B2 (en) 2007-10-17 2015-12-29 Covidien Lp Embolus removal systems with baskets
US8088140B2 (en) 2008-05-19 2012-01-03 Mindframe, Inc. Blood flow restorative and embolus removal methods
US9198687B2 (en) 2007-10-17 2015-12-01 Covidien Lp Acute stroke revascularization/recanalization systems processes and products thereby
US10123803B2 (en) 2007-10-17 2018-11-13 Covidien Lp Methods of managing neurovascular obstructions
US20100256600A1 (en) 2009-04-04 2010-10-07 Ferrera David A Neurovascular otw pta balloon catheter and delivery system
US20100174309A1 (en) 2008-05-19 2010-07-08 Mindframe, Inc. Recanalization/revascularization and embolus addressing systems including expandable tip neuro-microcatheter
US8066757B2 (en) 2007-10-17 2011-11-29 Mindframe, Inc. Blood flow restoration and thrombus management methods
US8585713B2 (en) 2007-10-17 2013-11-19 Covidien Lp Expandable tip assembly for thrombus management
US11337714B2 (en) 2007-10-17 2022-05-24 Covidien Lp Restoring blood flow and clot removal during acute ischemic stroke
DE102008028308A1 (de) 2007-10-18 2009-04-23 Acandis Gmbh & Co. Kg Vaskuläres Implantat und Verfahren zum Herstellen eines derartigen Implantats
US20090192455A1 (en) 2008-01-07 2009-07-30 David Ferrera Novel enhanced ptna rapid exchange type of catheter system
US9259225B2 (en) 2008-02-19 2016-02-16 St. Jude Medical, Cardiology Division, Inc. Medical devices for treating a target site and associated method
US20090228029A1 (en) 2008-03-05 2009-09-10 Neuro Vasx, Inc. Aneurysm shield anchoring device
US20130165967A1 (en) 2008-03-07 2013-06-27 W.L. Gore & Associates, Inc. Heart occlusion devices
US9119607B2 (en) 2008-03-07 2015-09-01 Gore Enterprise Holdings, Inc. Heart occlusion devices
US9138213B2 (en) 2008-03-07 2015-09-22 W.L. Gore & Associates, Inc. Heart occlusion devices
DE102008015781B4 (de) 2008-03-26 2011-09-29 Malte Neuss Vorrichtung zum Verschluss von Defekten im Gefäßsystem
WO2009124288A1 (fr) 2008-04-04 2009-10-08 Reverse Medical Corporation Système de microcathéter à utilités multiples et procédé d’utilisation
WO2009126935A2 (fr) 2008-04-11 2009-10-15 Mindframe, Inc. Neuro-microcathéter monorail pour la délivrance de dispositifs médicaux pour traiter un accident vasculaire cérébral, procédés et produits associés
JP5610542B2 (ja) 2008-04-21 2014-10-22 コヴィディエン リミテッド パートナーシップ ブレードボール塞栓装置および送達システム
US11471163B2 (en) 2008-05-01 2022-10-18 Aneuclose Llc Intrasaccular aneurysm occlusion device with net or mesh expanded by string-of-pearls embolies
US20180125500A1 (en) 2008-05-01 2018-05-10 Aneuclose Llc Intrasacular Aneurysm Occlusion Device with Mesh-Filled Loops
US20200100795A1 (en) 2008-05-01 2020-04-02 Aneuclose Llc "Bowl-of-Spaghetti" Type Intrasacular Aneurysm Occlusion Device
US10028747B2 (en) 2008-05-01 2018-07-24 Aneuclose Llc Coils with a series of proximally-and-distally-connected loops for occluding a cerebral aneurysm
US10716573B2 (en) 2008-05-01 2020-07-21 Aneuclose Janjua aneurysm net with a resilient neck-bridging portion for occluding a cerebral aneurysm
US20190365472A1 (en) 2010-10-21 2019-12-05 Aneuclose Llc Using 3D Imaging and 3D Printing to Occlude a Cerebral Aneurysm
JP2011519300A (ja) 2008-05-01 2011-07-07 アニュクローズ エルエルシー 動脈瘤閉塞装置
US20160374690A9 (en) 2010-10-21 2016-12-29 Robert A. Connor Devices and Methods for Occluding a Cerebral Aneurysm
US20160206321A1 (en) 2008-05-01 2016-07-21 Aneuclose Llc Aneurysm Occlusion Device with Sequence of Shape-Changing Embolic Members
WO2009135166A2 (fr) 2008-05-02 2009-11-05 Sequent Medical Inc. Dispositifs filamentaires pour le traitement de défauts vasculaires
US8454632B2 (en) 2008-05-12 2013-06-04 Xlumena, Inc. Tissue anchor for securing tissue layers
BRPI0916353A2 (pt) 2008-07-22 2018-06-12 Micro Therapeutics Inc dispositivos de remodelação
US8262692B2 (en) 2008-09-05 2012-09-11 Merlin Md Pte Ltd Endovascular device
US20100069948A1 (en) 2008-09-12 2010-03-18 Micrus Endovascular Corporation Self-expandable aneurysm filling device, system and method of placement
WO2010048177A2 (fr) 2008-10-20 2010-04-29 IMDS, Inc. Systèmes et procédés de traitement d'un anévrisme et d'occlusion vasculaire
WO2010121037A1 (fr) 2009-04-15 2010-10-21 Microvention, Inc. Systeme de mise en place d'implant
WO2010120694A1 (fr) 2009-04-16 2010-10-21 Boston Scientific Scimed, Inc. Contact électrique pour système de mise en place de dispositif d'occlusion
US20120071911A1 (en) 2009-05-20 2012-03-22 University Of Miami Spherical helix embolic coils for the treatment of cerebral aneurysms
US9693781B2 (en) 2009-06-17 2017-07-04 Coherex Medical, Inc. Medical device for modification of left atrial appendage and related systems and methods
US8740961B2 (en) 2009-08-13 2014-06-03 Richard Eustis Fulton, III Method for treating a target site in a vascular body channel
JP2013509914A (ja) 2009-11-05 2013-03-21 シークエント メディカル， インコーポレイテッド 複数層フィラメント状デバイスまたは血管障害処置
WO2011057277A2 (fr) 2009-11-09 2011-05-12 Nfocus Neuromedical, Inc. Caractéristiques de dispositif d'embolisation à balle tressée
DE102009056450A1 (de) 2009-12-01 2011-06-09 Acandis Gmbh & Co. Kg Medizinische Vorrichtung zur Einfuhr in ein Hohlorgan und Verfahren zur Herstellung einer solchen Vorrichtung
DE102009058132B4 (de) 2009-12-12 2014-07-24 Bentley Surgical Gmbh Zylindrischer Okkluder zur Abdichtung hohlzylindrischer Körpergefäße
CN102188300B (zh) 2010-03-02 2014-05-28 上海微创医疗器械（集团）有限公司 一种动脉瘤手术装置
ES2403009T3 (es) 2010-05-23 2013-05-13 Occlutech Holding Ag Dispositivo médico trenzado y método para su fabricación
EP2399524A1 (fr) 2010-06-22 2011-12-28 Occlutech Holding AG Implant médical et son procédé de fabrication
US9561308B2 (en) 2010-06-25 2017-02-07 Fort Wayne Metal Research Products Corporation Biodegradable composite wire for medical devices
JP2012030497A (ja) 2010-07-30 2012-02-16 Hosokawa Yoko Co Ltd 共押出フィルムおよびこれを用いた袋
CN103179909A (zh) 2010-09-06 2013-06-26 诺沃泰科医药股份有限公司 用于闭合血管中的开口或空腔的装置
EP2613735B1 (fr) 2010-09-10 2018-05-09 Covidien LP Dispositifs utilisés pour le traitement d'anomalies vasculaires
US20130066357A1 (en) 2010-09-10 2013-03-14 Maria Aboytes Devices and methods for the treatment of vascular defects
CN101933850B (zh) 2010-09-16 2012-07-18 先健科技(深圳)有限公司 封堵器及其制造方法
GB2483885B (en) 2010-09-23 2014-12-24 Dyson Technology Ltd A filter assembly for a vacuum cleaning appliance
US20120172973A1 (en) 2010-12-30 2012-07-05 Cook Medical Technologies Llc Self-expanding occlusion device
KR102311421B1 (ko) 2011-01-17 2021-10-13 아르티오 메디컬 인크. 볼스텐트 장치 및 사용방법
CN103442653B (zh) 2011-02-11 2016-06-01 柯惠有限合伙公司 两阶段展开动脉瘤栓塞装置
DE102011011869A1 (de) 2011-02-22 2012-08-23 Phenox Gmbh Implantat
US10398444B2 (en) 2011-03-30 2019-09-03 Noha, Llc Advanced endovascular clip and method of using same
US10028745B2 (en) 2011-03-30 2018-07-24 Noha, Llc Advanced endovascular clip and method of using same
US20120283768A1 (en) 2011-05-05 2012-11-08 Sequent Medical Inc. Method and apparatus for the treatment of large and giant vascular defects
DE102011102955B4 (de) 2011-05-31 2018-05-03 Acandis Gmbh & Co. Kg Medizinisches Implantat zur Anordnung eines Hohlkörpers, insbesondere eines Aneurysmas, und Verfahren zum Herstellen eines medizinischen Implantats
US20120330341A1 (en) 2011-06-22 2012-12-27 Becking Frank P Folded-Flat Aneurysm Embolization Devices
WO2013005195A1 (fr) 2011-07-07 2013-01-10 Jayandiran Pillai Dispositif d'occlusion d'anévrisme
US9161837B2 (en) 2011-07-27 2015-10-20 The Cleveland Clinic Foundation Apparatus, system, and method for treating a regurgitant heart valve
JP6100454B2 (ja) 2011-07-29 2017-03-22 アクセスポイント テクノロジーズ有限会社 生体管腔閉塞装置
US9198668B2 (en) 2011-08-04 2015-12-01 Cook Medical Technologies Llc Cerebral aneurysm closure device
EP4529864A3 (fr) 2011-08-05 2025-06-04 Route 92 Medical, Inc. Système de traitement d'un accident ischémique cérébral aigu
US20140343602A1 (en) * 2011-08-19 2014-11-20 Brian J. Cox Expandable occlusion device and methods
EP2567663A1 (fr) 2011-09-09 2013-03-13 Occlutech Holding AG Dispositif de fermeture médicale démontable, procédé et système médical pour fournir un objet
US9216076B2 (en) 2011-09-09 2015-12-22 Endoluminal Sciences Pty. Ltd. Means for controlled sealing of endovascular devices
EP2763602B1 (fr) 2011-10-05 2020-07-01 Pulsar Vascular, Inc. Dispositifs et systèmes pour enfermer une ouverture anatomique
US8261648B1 (en) 2011-10-17 2012-09-11 Sequent Medical Inc. Braiding mechanism and methods of use
EP2596754A1 (fr) 2011-11-23 2013-05-29 Occlutech Holding AG Implant médical et son procédé de fabrication
EP2800528A4 (fr) 2012-01-06 2015-12-02 Inceptus Medical LLC Dispositifs d'occlusion expansibles et procédés d'utilisation
EP3456271A1 (fr) 2012-01-17 2019-03-20 Metactive Medical, Inc. Dispositif d'occlusion expansible a corps metallique
US9113890B2 (en) * 2012-02-06 2015-08-25 Aga Medical Corporation Devices and methods for occluding vascular abnormalities
DE102012102844B4 (de) 2012-04-02 2020-03-19 Acandis Gmbh Okklusionsvorrichtung zur Implantation innerhalb eines Aneurysmas und Anordnung mit einer derartigen Okklusionsvorrichtung
WO2013152327A1 (fr) 2012-04-06 2013-10-10 Merlin Md Pte Ltd. Dispositifs et méthodes pour le traitement d'un anévrisme
US20150133989A1 (en) 2012-04-20 2015-05-14 Inceptus Medical, Llc Expandable occlusion devices and methods of use
AU2013271845B2 (en) 2012-06-04 2017-04-13 Penumbra, Inc. Aneurysm occlusion system and method
DE102012107175B4 (de) 2012-08-06 2015-08-13 Acandis Gmbh & Co. Kg Medizinische Verschlussvorrichtung und System mit einer derartigen Verschlussvorrichtung
JP6533463B2 (ja) 2012-08-22 2019-06-19 フェノックス ゲーエムベーハーＰｈｅｎｏｘ Ｇｍｂｈ インプラント
DE102012111223A1 (de) 2012-11-21 2014-05-22 Jotec Gmbh Gefäßimplantat mit asymmetrischen Stentfedern
US10342546B2 (en) 2013-01-14 2019-07-09 Microvention, Inc. Occlusive device
CN104905828B (zh) 2013-02-04 2018-08-07 先健科技(深圳)有限公司 一种具有可变夹角的扁平盘面的封堵器
CN103099652B (zh) 2013-02-19 2015-08-12 湖南埃普特医疗器械有限公司 一种左心耳封堵装置以及一种输送系统
US10716549B2 (en) 2013-03-05 2020-07-21 St. Jude Medical, Cardiology Division, Inc. Medical device for treating a target site
US9681861B2 (en) 2013-03-11 2017-06-20 St. Jude Medical, Cardiology Division, Inc. Percutaneous catheter directed collapsible medical closure device
US8715314B1 (en) 2013-03-15 2014-05-06 Insera Therapeutics, Inc. Vascular treatment measurement methods
DE102013106031B4 (de) 2013-06-11 2015-07-02 Acandis Gmbh & Co. Kg Medizinisches Implantat und System mit einem derartigen Implantat
US9078658B2 (en) 2013-08-16 2015-07-14 Sequent Medical, Inc. Filamentary devices for treatment of vascular defects
US9955976B2 (en) 2013-08-16 2018-05-01 Sequent Medical, Inc. Filamentary devices for treatment of vascular defects
US10076399B2 (en) 2013-09-13 2018-09-18 Covidien Lp Endovascular device engagement
CN105722474B (zh) 2013-11-13 2018-09-21 柯惠有限合伙公司 以原电池方式辅助医疗装置与血栓的附着
EP3082619B1 (fr) 2013-12-20 2024-04-10 Terumo Corporation Occlusion vasculaire
US11076860B2 (en) 2014-03-31 2021-08-03 DePuy Synthes Products, Inc. Aneurysm occlusion device
US11154302B2 (en) 2014-03-31 2021-10-26 DePuy Synthes Products, Inc. Aneurysm occlusion device
WO2015160721A1 (fr) 2014-04-14 2015-10-22 Sequent Medical Inc. Dispositifs pour interventions vasculaires thérapeutiques
US9629635B2 (en) 2014-04-14 2017-04-25 Sequent Medical, Inc. Devices for therapeutic vascular procedures
MX381828B (es) 2014-04-30 2025-03-13 Cerus Endovascular Ltd Dispositivo de oclusión.
US9060777B1 (en) 2014-05-28 2015-06-23 Tw Medical Technologies, Llc Vaso-occlusive devices and methods of use
EP3148481A4 (fr) 2014-05-28 2017-05-03 Stryker European Holdings I, LLC Dispositifs vaso-occlusifs et procédés d'utilisation
CN105792879A (zh) 2014-06-04 2016-07-20 恩菲纽姆血管技术有限公司 低径向力血管设备和闭塞方法
EP3171793B1 (fr) 2014-08-14 2024-07-24 Microvention, Inc. Dispositifs filamenteux pour le traitement d'anomalies vasculaires
WO2016067646A1 (fr) 2014-10-27 2016-05-06 テルモ株式会社 Dispositif médical
CN104605909A (zh) 2014-12-30 2015-05-13 先健科技(深圳)有限公司 封堵器及其制作方法以及用于制作封堵器的编织网管
US20200138422A1 (en) 2015-01-20 2020-05-07 Neurogami Medical, Inc. Vascular implant
WO2016118420A1 (fr) 2015-01-20 2016-07-28 Neurogami Medical, Inc. Microgreffe pour le traitement d'anévrismes intracrâniens et procédé d'utilisation
US20160213380A1 (en) 2015-01-22 2016-07-28 Boston Scientific Scimed, Inc. Occlusion device having spherical secondary shape and mandrel for forming same
CA2976260C (fr) 2015-02-25 2024-02-06 Galaxy Therapeutics, Llc Systeme et procede pour traiter les anevrismes
US10159490B2 (en) 2015-05-08 2018-12-25 Stryker European Holdings I, Llc Vaso-occlusive devices
CN104958087B (zh) 2015-07-28 2018-09-25 杭州诺茂医疗科技有限公司 一种左心耳封堵器
CN105054985B (zh) 2015-07-28 2018-05-01 杭州诺茂医疗科技有限公司 一种改进的左心耳封堵器
CN204971420U (zh) 2015-08-12 2016-01-20 上海形状记忆合金材料有限公司 一种动脉导管未闭封堵器
CN204931771U (zh) 2015-09-18 2016-01-06 王奎重 一种颅内动脉瘤介入栓塞治疗装置
US10478194B2 (en) 2015-09-23 2019-11-19 Covidien Lp Occlusive devices
CA3005686A1 (fr) 2015-12-07 2017-06-15 Cerus Endovascular Limited Dispositif d'occlusion
WO2017106567A1 (fr) 2015-12-15 2017-06-22 Nsvascular, Inc. Déviateurs de flux intrasacculaire à film fin et procédés associés
CA3014316C (fr) 2016-02-10 2025-08-12 Microvention, Inc. Dispositifs pour occlusion vasculaire
WO2017153603A1 (fr) 2016-03-11 2017-09-14 Cerus Endovascular Limited Dispositif d'occlusion
US10952739B2 (en) 2016-03-11 2021-03-23 Sequent Medical, Inc. Systems and methods for delivery of stents and stent-like devices
EP3429479A4 (fr) 2016-03-17 2019-10-23 Swaminathan Jayaraman Structures anatomiques bloquantes
WO2017201316A1 (fr) 2016-05-18 2017-11-23 Microvention, Inc. Confinement embolique
JP7059187B2 (ja) 2016-08-29 2022-04-25 テルモ株式会社 医療デバイス
JP2019526324A (ja) 2016-09-14 2019-09-19 メディノール リミテッドＭｅｄｉｎｏｌ Ｌｔｄ． 動脈瘤閉塞デバイス
US20180206851A1 (en) 2016-10-19 2018-07-26 Daniel E. Walzman Hydrogel intrasaccular occlusion device
FI3528717T3 (fi) 2016-10-24 2024-08-09 Inari Medical Inc Laitteita verisuonitukoksen hoitamiseen
US11045177B2 (en) 2016-11-02 2021-06-29 Daniel Ezra Walzman Orientable intracranial occlusion device and method
US10603070B2 (en) 2016-12-05 2020-03-31 Daniel E. Walzman Alternative use for hydrogel intrasaccular occlusion device with a spring for structural support
US12426885B2 (en) 2016-12-05 2025-09-30 Daniel Ezra Walzman Mesh cap for ameliorating outpouchings
US10548607B2 (en) 2016-12-05 2020-02-04 Daniel Ezra Walzman Mesh caps
US10543015B2 (en) 2016-12-05 2020-01-28 Daniel Ezra Walzman Mesh disc for saccular aneurysms and cover for saccular out-pouching
US10448970B2 (en) 2016-12-05 2019-10-22 Daniel E. Walzman Alternative use for hydrogel intrasaccular occlusion device with telescoping central support element
FR3061647B1 (fr) 2017-01-11 2020-06-19 Universite De Montpellier Dispositif intra-anevrismal
CA3054556A1 (fr) 2017-02-23 2018-08-30 DePuy Synthes Products, Inc. Dispositif pour anevrisme et systeme d'administration
US10881413B2 (en) 2017-03-24 2021-01-05 Sequent Medical, Inc. Systems and methods for embolization of body structures
CA3073232C (fr) 2017-08-21 2023-08-29 Cerus Endovascular Limited Dispositif d'occlusion
US10751065B2 (en) 2017-12-22 2020-08-25 DePuy Synthes Products, Inc. Aneurysm device and delivery system
US10716574B2 (en) 2017-12-22 2020-07-21 DePuy Synthes Products, Inc. Aneurysm device and delivery method
US20190216467A1 (en) 2018-01-12 2019-07-18 Mg Stroke Analytics Inc. Apparatus and Methods for Intravascular Treatment of Aneurysms
US11185335B2 (en) 2018-01-19 2021-11-30 Galaxy Therapeutics Inc. System for and method of treating aneurysms
US10905430B2 (en) 2018-01-24 2021-02-02 DePuy Synthes Products, Inc. Aneurysm device and delivery system
JP2021513905A (ja) 2018-02-23 2021-06-03 ネウルヴァナ メディカル エルエルシー 新規の強化されたオーブ状の嚢内デバイス
US11596412B2 (en) 2018-05-25 2023-03-07 DePuy Synthes Products, Inc. Aneurysm device and delivery system
US11058430B2 (en) 2018-05-25 2021-07-13 DePuy Synthes Products, Inc. Aneurysm device and delivery system
US10939915B2 (en) 2018-05-31 2021-03-09 DePuy Synthes Products, Inc. Aneurysm device and delivery system
IL269005A (en) 2018-09-12 2019-10-31 Depuy Synthes Products Inc Improved aneurysm occlusion device
US11123077B2 (en) 2018-09-25 2021-09-21 DePuy Synthes Products, Inc. Intrasaccular device positioning and deployment system
US11076861B2 (en) 2018-10-12 2021-08-03 DePuy Synthes Products, Inc. Folded aneurysm treatment device and delivery method
US11272939B2 (en) 2018-12-18 2022-03-15 DePuy Synthes Products, Inc. Intrasaccular flow diverter for treating cerebral aneurysms
US10807605B2 (en) 2018-12-19 2020-10-20 Waymo Llc Systems and methods for detecting and dynamically mitigating driver fatigue
WO2020139544A2 (fr) 2018-12-27 2020-07-02 Stryker Corporation Dispositif de réduction de flux intra-sacculaire multi-couche conformable et ses procédés de fabrication
EP3911253A4 (fr) 2019-01-18 2022-03-09 Neurogami Medical, Inc. Implant vasculaire
JP7469323B2 (ja) 2019-03-15 2024-04-16 マイクロベンション インコーポレイテッド 血管障害の治療のためのフィラメント状デバイス
WO2020190630A1 (fr) 2019-03-15 2020-09-24 Sequent Medical, Inc. Dispositifs filamenteux munis d'une articulation flexible pour le traitement d'anomalies vasculaires
WO2020190639A1 (fr) 2019-03-15 2020-09-24 Sequent Medical, Inc. Dispositifs filamenteux pour le traitement de défauts vasculaires
US11337706B2 (en) 2019-03-27 2022-05-24 DePuy Synthes Products, Inc. Aneurysm treatment device
US11058431B2 (en) 2019-05-25 2021-07-13 Galaxy Therapeutics, Inc. Systems and methods for treating aneurysms
US11523838B2 (en) 2019-06-12 2022-12-13 Covidien Lp Retrieval of material from corporeal lumens
US10561411B1 (en) 2019-07-26 2020-02-18 Little Engine, LLC Flush anchor snap-off apparatus
DE102019121546B4 (de) 2019-08-09 2024-02-08 Acandis Gmbh Medizinisches Set sowie medizinisches System zur Behandlung von Aneurysmen
DE102019121554B4 (de) 2019-08-09 2025-07-10 Acandis Gmbh Medizinisches Set zur Behandlung von Aneurysmen, Herstellungsverfahren sowie medizinisches System zur Behandlung von Aneurysmen
EP4027943A4 (fr) 2019-09-12 2023-09-06 Daniel Ezra Walzmann Capuchon à mailles pour atténuer les diverticules
WO2021092618A1 (fr) 2019-11-04 2021-05-14 Covidien Lp Dispositifs, systèmes et procédés pour le traitement d'anévrismes intracrâniens
US20220054286A1 (en) 2019-11-06 2022-02-24 Mg Stroke Analytics Inc. Stent and Catheter Systems for Treatment of Unstable Plaque and Cerebral Aneurysm
US11376013B2 (en) 2019-11-18 2022-07-05 DePuy Synthes Products, Inc. Implant delivery system with braid cup formation
US11457926B2 (en) 2019-12-18 2022-10-04 DePuy Synthes Products, Inc. Implant having an intrasaccular section and intravascular section
US11432822B2 (en) 2020-02-14 2022-09-06 DePuy Synthes Products, Inc. Intravascular implant deployment system
US11406404B2 (en) 2020-02-20 2022-08-09 Cerus Endovascular Limited Clot removal distal protection methods
US12023034B2 (en) 2020-03-11 2024-07-02 Microvention, Inc. Devices for treatment of vascular defects

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4106670A2 (fr) * 2020-02-20 2022-12-28 Cerus Endovascular Limited Méthodes de protection distale d'élimination de caillots

Also Published As

Publication number Publication date
EP3136986A1 (fr) 2017-03-08
JP2019205893A (ja) 2019-12-05
CN106456183A (zh) 2017-02-22
CA2946078C (fr) 2023-03-14
JP2021090803A (ja) 2021-06-17
IL248515A0 (en) 2016-12-29
JP2024125345A (ja) 2024-09-18
JP7160973B2 (ja) 2022-10-25
US20150313605A1 (en) 2015-11-05
EP3970635A1 (fr) 2022-03-23
MX2016014236A (es) 2017-05-30
US12414775B1 (en) 2025-09-16
US20220323084A1 (en) 2022-10-13
EP3510945A1 (fr) 2019-07-17
ES2732752T3 (es) 2019-11-25
US12029431B2 (en) 2024-07-09
US20200038035A1 (en) 2020-02-06
US11389174B2 (en) 2022-07-19
US11284901B2 (en) 2022-03-29
MX2021004542A (es) 2021-06-15
MX381828B (es) 2025-03-13
WO2015166013A1 (fr) 2015-11-05
US20250366860A1 (en) 2025-12-04
JP2022188259A (ja) 2022-12-20
US10130372B2 (en) 2018-11-20
JP6841874B2 (ja) 2021-03-10
CN106456183B (zh) 2019-09-20
JP6571760B2 (ja) 2019-09-04
US20190059909A1 (en) 2019-02-28
ES2905419T3 (es) 2022-04-08
JP2017516605A (ja) 2017-06-22
CA2946078A1 (fr) 2015-11-05
EP3510945B1 (fr) 2021-11-10

Similar Documents

Publication Publication Date Title
US12414775B1 (en) Occlusion device
US12251112B2 (en) Occlusion device
US12076022B2 (en) Occlusion device
HK40068168A (en) Occlusion device
HK40011380B (en) Occlusion device
HK40011380A (en) Occlusion device
HK40028805B (en) Occlusion device
HK40028805A (en) Occlusion device
HK1261731A1 (en) Occlusion device
HK1261731B (en) Occlusion device
HK1234631A1 (en) Occlusion device

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180326

RIC1 Information provided on ipc code assigned before grant

Ipc: A61B 17/00 20060101ALN20180927BHEP

Ipc: A61B 17/12 20060101AFI20180927BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61B 17/12 20060101AFI20181001BHEP

Ipc: A61B 17/00 20060101ALN20181001BHEP

INTG Intention to grant announced

Effective date: 20181102

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015028441

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1120700

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190515

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20190417

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190817

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2732752

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20191125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190718

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1120700

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190417

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190429

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190817

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015028441

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190430

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190430

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190430

26N No opposition filed

Effective date: 20200120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20150429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602015028441

Country of ref document: DE

Representative=s name: WUESTHOFF & WUESTHOFF, PATENTANWAELTE PARTG MB, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602015028441

Country of ref document: DE

Representative=s name: WUESTHOFF & WUESTHOFF PATENTANWAELTE UND RECHT, DE

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230515

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602015028441

Country of ref document: DE

Owner name: STRYKER IRELAND TECHNOLOGY LTD., CARRIGTWOHILL, IE

Free format text: FORMER OWNER: CERUS ENDOVASCULAR LIMITED, OXFORD, OXFORDSHIRE, GB

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250310

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250306

Year of fee payment: 11

Ref country code: IT

Payment date: 20250320

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250305

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250509

Year of fee payment: 11